WO2023115158A1 - Coating compositions - Google Patents
Coating compositions Download PDFInfo
- Publication number
- WO2023115158A1 WO2023115158A1 PCT/AU2022/051584 AU2022051584W WO2023115158A1 WO 2023115158 A1 WO2023115158 A1 WO 2023115158A1 AU 2022051584 W AU2022051584 W AU 2022051584W WO 2023115158 A1 WO2023115158 A1 WO 2023115158A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- days
- mixtures
- coating
- film
- Prior art date
Links
- 239000008199 coating composition Substances 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 502
- 238000000576 coating method Methods 0.000 claims abstract description 98
- 229910052751 metal Inorganic materials 0.000 claims abstract description 78
- 239000002184 metal Substances 0.000 claims abstract description 78
- 230000001775 anti-pathogenic effect Effects 0.000 claims abstract description 44
- 239000000341 volatile oil Substances 0.000 claims abstract description 33
- 125000002091 cationic group Chemical group 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 20
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 6
- 239000011248 coating agent Substances 0.000 claims description 81
- 239000010408 film Substances 0.000 claims description 68
- 229920000642 polymer Polymers 0.000 claims description 67
- 241000700605 Viruses Species 0.000 claims description 48
- -1 polyethylene terephthalate Polymers 0.000 claims description 47
- 244000052769 pathogen Species 0.000 claims description 44
- 150000001875 compounds Chemical class 0.000 claims description 40
- 241000894006 Bacteria Species 0.000 claims description 36
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 31
- 229920006317 cationic polymer Polymers 0.000 claims description 31
- 229940117916 cinnamic aldehyde Drugs 0.000 claims description 31
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 claims description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- 230000001717 pathogenic effect Effects 0.000 claims description 27
- 239000000463 material Substances 0.000 claims description 24
- 230000000844 anti-bacterial effect Effects 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 22
- 230000000840 anti-viral effect Effects 0.000 claims description 21
- 241000233866 Fungi Species 0.000 claims description 20
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 claims description 20
- 235000019441 ethanol Nutrition 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 18
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims description 18
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 17
- 239000004472 Lysine Substances 0.000 claims description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004411 aluminium Substances 0.000 claims description 14
- 229910052782 aluminium Inorganic materials 0.000 claims description 14
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000010949 copper Substances 0.000 claims description 12
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 11
- QPLDLSVMHZLSFG-UHFFFAOYSA-N Copper oxide Chemical compound [Cu]=O QPLDLSVMHZLSFG-UHFFFAOYSA-N 0.000 claims description 11
- 241000195493 Cryptophyta Species 0.000 claims description 11
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 claims description 11
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 claims description 11
- 235000007746 carvacrol Nutrition 0.000 claims description 11
- 229910052802 copper Inorganic materials 0.000 claims description 11
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 11
- 241001678559 COVID-19 virus Species 0.000 claims description 10
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 10
- 239000000956 alloy Substances 0.000 claims description 10
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 10
- 150000002739 metals Chemical class 0.000 claims description 10
- 239000003921 oil Substances 0.000 claims description 10
- 239000003973 paint Substances 0.000 claims description 10
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 9
- 239000005844 Thymol Substances 0.000 claims description 9
- 229910045601 alloy Inorganic materials 0.000 claims description 9
- 229920002635 polyurethane Polymers 0.000 claims description 9
- 229910052709 silver Inorganic materials 0.000 claims description 9
- 239000004332 silver Substances 0.000 claims description 9
- 229960000790 thymol Drugs 0.000 claims description 9
- 239000005751 Copper oxide Substances 0.000 claims description 8
- 150000001298 alcohols Chemical class 0.000 claims description 8
- 125000001931 aliphatic group Chemical group 0.000 claims description 8
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 claims description 8
- 229910000431 copper oxide Inorganic materials 0.000 claims description 8
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 claims description 8
- 229920001519 homopolymer Polymers 0.000 claims description 8
- 229930195733 hydrocarbon Natural products 0.000 claims description 8
- 150000002430 hydrocarbons Chemical class 0.000 claims description 8
- 239000000178 monomer Substances 0.000 claims description 8
- 239000004814 polyurethane Substances 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 7
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 230000003373 anti-fouling effect Effects 0.000 claims description 7
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 150000002170 ethers Chemical class 0.000 claims description 7
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 7
- 150000002576 ketones Chemical class 0.000 claims description 7
- 229920003023 plastic Polymers 0.000 claims description 7
- 239000004033 plastic Substances 0.000 claims description 7
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 6
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 6
- 239000000443 aerosol Substances 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- 230000000843 anti-fungal effect Effects 0.000 claims description 6
- 239000004067 bulking agent Substances 0.000 claims description 6
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- OHPZPBNDOVQJMH-UHFFFAOYSA-N n-ethyl-4-methylbenzenesulfonamide Chemical compound CCNS(=O)(=O)C1=CC=C(C)C=C1 OHPZPBNDOVQJMH-UHFFFAOYSA-N 0.000 claims description 6
- 239000004014 plasticizer Substances 0.000 claims description 6
- 229920000728 polyester Polymers 0.000 claims description 6
- 239000001797 sucrose acetate isobutyrate Substances 0.000 claims description 6
- UVGUPMLLGBCFEJ-SWTLDUCYSA-N sucrose acetate isobutyrate Chemical compound CC(C)C(=O)O[C@H]1[C@H](OC(=O)C(C)C)[C@@H](COC(=O)C(C)C)O[C@@]1(COC(C)=O)O[C@@H]1[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](COC(C)=O)O1 UVGUPMLLGBCFEJ-SWTLDUCYSA-N 0.000 claims description 6
- 235000010983 sucrose acetate isobutyrate Nutrition 0.000 claims description 6
- 239000010677 tea tree oil Substances 0.000 claims description 6
- 229940111630 tea tree oil Drugs 0.000 claims description 6
- 239000002562 thickening agent Substances 0.000 claims description 6
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 6
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 239000003125 aqueous solvent Substances 0.000 claims description 5
- 150000001735 carboxylic acids Chemical class 0.000 claims description 5
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 5
- 229940041616 menthol Drugs 0.000 claims description 5
- 150000003505 terpenes Chemical class 0.000 claims description 5
- 239000010936 titanium Substances 0.000 claims description 5
- 229910052719 titanium Inorganic materials 0.000 claims description 5
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 239000005973 Carvone Substances 0.000 claims description 4
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 claims description 4
- 241000723346 Cinnamomum camphora Species 0.000 claims description 4
- 235000005979 Citrus limon Nutrition 0.000 claims description 4
- 244000131522 Citrus pyriformis Species 0.000 claims description 4
- 239000005770 Eugenol Substances 0.000 claims description 4
- 241000192125 Firmicutes Species 0.000 claims description 4
- 240000006927 Foeniculum vulgare Species 0.000 claims description 4
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 4
- 240000003553 Leptospermum scoparium Species 0.000 claims description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 4
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 4
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 claims description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 4
- 244000223014 Syzygium aromaticum Species 0.000 claims description 4
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 claims description 4
- 229930008380 camphor Natural products 0.000 claims description 4
- 229960000846 camphor Drugs 0.000 claims description 4
- 229960002217 eugenol Drugs 0.000 claims description 4
- 229910052749 magnesium Inorganic materials 0.000 claims description 4
- 239000011777 magnesium Substances 0.000 claims description 4
- 229910052750 molybdenum Inorganic materials 0.000 claims description 4
- 239000011733 molybdenum Substances 0.000 claims description 4
- 239000008247 solid mixture Substances 0.000 claims description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 claims description 4
- 230000007704 transition Effects 0.000 claims description 4
- 239000002023 wood Substances 0.000 claims description 4
- 229910052726 zirconium Inorganic materials 0.000 claims description 4
- DLKDEVCJRCPTLN-UHFFFAOYSA-N 2-butylisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCC)C(=O)C2=C1 DLKDEVCJRCPTLN-UHFFFAOYSA-N 0.000 claims description 3
- VPLDXHDOGVIETL-UHFFFAOYSA-N 2-propan-2-ylisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(C(C)C)C(=O)C2=C1 VPLDXHDOGVIETL-UHFFFAOYSA-N 0.000 claims description 3
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 3
- BQGCEVQVMURRGP-UHFFFAOYSA-N C(C1=CC=CC=C1)S(=O)(=O)N.C=O.NC(=O)N Chemical compound C(C1=CC=CC=C1)S(=O)(=O)N.C=O.NC(=O)N BQGCEVQVMURRGP-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 235000005747 Carum carvi Nutrition 0.000 claims description 3
- 240000000467 Carum carvi Species 0.000 claims description 3
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 3
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 claims description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 3
- 244000246386 Mentha pulegium Species 0.000 claims description 3
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 3
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 3
- 240000005125 Myrtus communis Species 0.000 claims description 3
- 235000013418 Myrtus communis Nutrition 0.000 claims description 3
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 3
- 239000000020 Nitrocellulose Substances 0.000 claims description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 3
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 3
- 240000002657 Thymus vulgaris Species 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- WUOACPNHFRMFPN-UHFFFAOYSA-N alpha-terpineol Chemical compound CC1=CCC(C(C)(C)O)CC1 WUOACPNHFRMFPN-UHFFFAOYSA-N 0.000 claims description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N anhydrous guanidine Natural products NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 3
- 239000012871 anti-fungal composition Substances 0.000 claims description 3
- 239000000440 bentonite Substances 0.000 claims description 3
- 229910000278 bentonite Inorganic materials 0.000 claims description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 239000004359 castor oil Substances 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 229920006217 cellulose acetate butyrate Polymers 0.000 claims description 3
- 150000003841 chloride salts Chemical class 0.000 claims description 3
- 229940043350 citral Drugs 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- SQIFACVGCPWBQZ-UHFFFAOYSA-N delta-terpineol Natural products CC(C)(O)C1CCC(=C)CC1 SQIFACVGCPWBQZ-UHFFFAOYSA-N 0.000 claims description 3
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 3
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 239000001087 glyceryl triacetate Substances 0.000 claims description 3
- 235000013773 glyceryl triacetate Nutrition 0.000 claims description 3
- 150000002334 glycols Chemical class 0.000 claims description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 3
- 229910052737 gold Inorganic materials 0.000 claims description 3
- 239000010931 gold Substances 0.000 claims description 3
- 229910021389 graphene Inorganic materials 0.000 claims description 3
- 235000001050 hortel pimenta Nutrition 0.000 claims description 3
- 239000007943 implant Substances 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 229940078863 isopropylphthalimide Drugs 0.000 claims description 3
- 239000002923 metal particle Substances 0.000 claims description 3
- 229940072395 n-butylphthalimide Drugs 0.000 claims description 3
- 229910052759 nickel Inorganic materials 0.000 claims description 3
- 229920001220 nitrocellulos Polymers 0.000 claims description 3
- 244000309711 non-enveloped viruses Species 0.000 claims description 3
- GCTMVWJHICUMRV-UHFFFAOYSA-N octan-3-yl diphenyl phosphate Chemical compound C=1C=CC=CC=1OP(=O)(OC(CC)CCCCC)OC1=CC=CC=C1 GCTMVWJHICUMRV-UHFFFAOYSA-N 0.000 claims description 3
- 125000005498 phthalate group Chemical class 0.000 claims description 3
- 239000000049 pigment Substances 0.000 claims description 3
- 229920001748 polybutylene Polymers 0.000 claims description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 3
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 229910052710 silicon Inorganic materials 0.000 claims description 3
- 239000010703 silicon Substances 0.000 claims description 3
- 229940070720 stearalkonium Drugs 0.000 claims description 3
- 125000005502 stearalkonium group Chemical group 0.000 claims description 3
- 229940102548 stearalkonium hectorite Drugs 0.000 claims description 3
- 210000004243 sweat Anatomy 0.000 claims description 3
- 229940116411 terpineol Drugs 0.000 claims description 3
- 239000001585 thymus vulgaris Substances 0.000 claims description 3
- 229910052718 tin Inorganic materials 0.000 claims description 3
- 239000011135 tin Substances 0.000 claims description 3
- 229960002622 triacetin Drugs 0.000 claims description 3
- 210000002268 wool Anatomy 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims 1
- 230000009467 reduction Effects 0.000 description 30
- 229920002413 Polyhexanide Polymers 0.000 description 19
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 17
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 16
- 230000000845 anti-microbial effect Effects 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- 239000000758 substrate Substances 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 15
- 235000018977 lysine Nutrition 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 230000002458 infectious effect Effects 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000002105 nanoparticle Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 10
- 239000010410 layer Substances 0.000 description 10
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 239000013078 crystal Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 6
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 5
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 5
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 5
- 238000002832 anti-viral assay Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 5
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 239000001361 adipic acid Substances 0.000 description 4
- 235000011037 adipic acid Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000002223 anti-pathogen Effects 0.000 description 4
- 229940093265 berberine Drugs 0.000 description 4
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229960005233 cineole Drugs 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 4
- 239000006916 nutrient agar Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 150000003138 primary alcohols Chemical class 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 150000003333 secondary alcohols Chemical class 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000003509 tertiary alcohols Chemical class 0.000 description 4
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- OAYXUHPQHDHDDZ-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethanol Chemical compound CCCCOCCOCCO OAYXUHPQHDHDDZ-UHFFFAOYSA-N 0.000 description 3
- SBASXUCJHJRPEV-UHFFFAOYSA-N 2-(2-methoxyethoxy)ethanol Chemical compound COCCOCCO SBASXUCJHJRPEV-UHFFFAOYSA-N 0.000 description 3
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 3
- POAOYUHQDCAZBD-UHFFFAOYSA-N 2-butoxyethanol Chemical compound CCCCOCCO POAOYUHQDCAZBD-UHFFFAOYSA-N 0.000 description 3
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 3
- 239000002028 Biomass Substances 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 3
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 3
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 3
- 230000032770 biofilm formation Effects 0.000 description 3
- 239000000919 ceramic Substances 0.000 description 3
- 235000000484 citronellol Nutrition 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 229920006037 cross link polymer Polymers 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 3
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 3
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 3
- 229920000740 poly(D-lysine) polymer Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- SDHMGKANHNMOSS-UHFFFAOYSA-N 1-aminoethanesulfonic acid Chemical compound CC(N)S(O)(=O)=O SDHMGKANHNMOSS-UHFFFAOYSA-N 0.000 description 2
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 description 2
- XDQFDSRZWFUALA-UHFFFAOYSA-N 5-methyl-2-propan-2-ylphenol;phenol Chemical compound OC1=CC=CC=C1.CC(C)C1=CC=C(C)C=C1O XDQFDSRZWFUALA-UHFFFAOYSA-N 0.000 description 2
- 229910017944 Ag—Cu Inorganic materials 0.000 description 2
- 229940123208 Biguanide Drugs 0.000 description 2
- 208000025721 COVID-19 Diseases 0.000 description 2
- 229910000684 Cobalt-chrome Inorganic materials 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 2
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000005058 Isophorone diisocyanate Substances 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- ZYEMGPIYFIJGTP-UHFFFAOYSA-N O-methyleugenol Chemical compound COC1=CC=C(CC=C)C=C1OC ZYEMGPIYFIJGTP-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004696 Poly ether ether ketone Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229920000180 alkyd Polymers 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 229930007050 cineol Natural products 0.000 description 2
- JOZKFWLRHCDGJA-UHFFFAOYSA-N citronellol acetate Chemical compound CC(=O)OCCC(C)CCC=C(C)C JOZKFWLRHCDGJA-UHFFFAOYSA-N 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000010952 cobalt-chrome Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000645 desinfectant Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000003822 epoxy resin Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000011133 lead Substances 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- ZQBAKBUEJOMQEX-UHFFFAOYSA-N phenyl salicylate Chemical compound OC1=CC=CC=C1C(=O)OC1=CC=CC=C1 ZQBAKBUEJOMQEX-UHFFFAOYSA-N 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 229920000647 polyepoxide Polymers 0.000 description 2
- 229920002530 polyetherether ketone Polymers 0.000 description 2
- 229920001522 polyglycol ester Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 2
- 239000002210 silicon-based material Substances 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000009637 wintergreen oil Substances 0.000 description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- DCSCXTJOXBUFGB-JGVFFNPUSA-N (R)-(+)-Verbenone Natural products CC1=CC(=O)[C@@H]2C(C)(C)[C@H]1C2 DCSCXTJOXBUFGB-JGVFFNPUSA-N 0.000 description 1
- DCSCXTJOXBUFGB-SFYZADRCSA-N (R)-(+)-verbenone Chemical compound CC1=CC(=O)[C@H]2C(C)(C)[C@@H]1C2 DCSCXTJOXBUFGB-SFYZADRCSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- DTOUUUZOYKYHEP-UHFFFAOYSA-N 1,3-bis(2-ethylhexyl)-5-methyl-1,3-diazinan-5-amine Chemical compound CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1 DTOUUUZOYKYHEP-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- DXENBVSHQHBTBD-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-1-(diaminomethylidene)guanidine Chemical compound NC(N)=NC(N)=NCC1=CC=C(Cl)C=C1 DXENBVSHQHBTBD-UHFFFAOYSA-N 0.000 description 1
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- GXDKXRIMUVUELI-UHFFFAOYSA-N 2-aminopropanedinitrile Chemical compound N#CC(N)C#N GXDKXRIMUVUELI-UHFFFAOYSA-N 0.000 description 1
- RNLHGQLZWXBQNY-UHFFFAOYSA-N 3-(aminomethyl)-3,5,5-trimethylcyclohexan-1-amine Chemical compound CC1(C)CC(N)CC(C)(CN)C1 RNLHGQLZWXBQNY-UHFFFAOYSA-N 0.000 description 1
- AZXBHGKSTNMAMK-UHFFFAOYSA-N 3-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=C(C)C=CC=C1O AZXBHGKSTNMAMK-UHFFFAOYSA-N 0.000 description 1
- WTWBUQJHJGUZCY-UHFFFAOYSA-N 4-Isopropyl benzaldehyde Natural products CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 description 1
- KJLPSBMDOIVXSN-UHFFFAOYSA-N 4-[4-[2-[4-(3,4-dicarboxyphenoxy)phenyl]propan-2-yl]phenoxy]phthalic acid Chemical compound C=1C=C(OC=2C=C(C(C(O)=O)=CC=2)C(O)=O)C=CC=1C(C)(C)C(C=C1)=CC=C1OC1=CC=C(C(O)=O)C(C(O)=O)=C1 KJLPSBMDOIVXSN-UHFFFAOYSA-N 0.000 description 1
- KFZXVMNBUMVKLN-UHFFFAOYSA-N 4-chloro-5-methyl-2-propan-2-ylphenol Chemical compound CC(C)C1=CC(Cl)=C(C)C=C1O KFZXVMNBUMVKLN-UHFFFAOYSA-N 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 235000004507 Abies alba Nutrition 0.000 description 1
- 244000101408 Abies amabilis Species 0.000 description 1
- 235000014081 Abies amabilis Nutrition 0.000 description 1
- 235000017894 Abies grandis Nutrition 0.000 description 1
- 229910018089 Al Ka Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229910018453 Al—Ka Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000003717 Boswellia sacra Nutrition 0.000 description 1
- 235000012035 Boswellia serrata Nutrition 0.000 description 1
- 240000007551 Boswellia serrata Species 0.000 description 1
- 240000004542 Capparis mitchellii Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- JOZKFWLRHCDGJA-LLVKDONJSA-N Citronellyl acetate Natural products CC(=O)OCC[C@H](C)CCC=C(C)C JOZKFWLRHCDGJA-LLVKDONJSA-N 0.000 description 1
- 240000004307 Citrus medica Species 0.000 description 1
- 229910000531 Co alloy Inorganic materials 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 240000004784 Cymbopogon citratus Species 0.000 description 1
- 235000017897 Cymbopogon citratus Nutrition 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 239000004908 Emulsion polymer Substances 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 240000001238 Gaultheria procumbens Species 0.000 description 1
- 235000007297 Gaultheria procumbens Nutrition 0.000 description 1
- 229920000028 Gradient copolymer Polymers 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 1
- BJIOGJUNALELMI-ONEGZZNKSA-N Isoeugenol Natural products COC1=CC(\C=C\C)=CC=C1O BJIOGJUNALELMI-ONEGZZNKSA-N 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- 240000005183 Lantana involucrata Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 244000165082 Lavanda vera Species 0.000 description 1
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 1
- 235000019501 Lemon oil Nutrition 0.000 description 1
- 235000016887 Leptospermum scoparium Nutrition 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000975794 Macropodid alphaherpesvirus 1 Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 244000304222 Melaleuca cajuputi Species 0.000 description 1
- 235000001167 Melaleuca cajuputi Nutrition 0.000 description 1
- 235000017710 Melaleuca viridiflora Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- QWZLBLDNRUUYQI-UHFFFAOYSA-M Methylbenzethonium chloride Chemical compound [Cl-].CC1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 QWZLBLDNRUUYQI-UHFFFAOYSA-M 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 235000010672 Monarda didyma Nutrition 0.000 description 1
- 244000179970 Monarda didyma Species 0.000 description 1
- 241000711466 Murine hepatitis virus Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 235000004098 Prunus caroliniana Nutrition 0.000 description 1
- 235000003893 Prunus dulcis var amara Nutrition 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000002911 Salvia sclarea Nutrition 0.000 description 1
- 244000182022 Salvia sclarea Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229910001347 Stellite Inorganic materials 0.000 description 1
- 244000303379 Styrax officinalis Species 0.000 description 1
- 235000001361 Styrax officinalis Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000125380 Terminalia tomentosa Species 0.000 description 1
- 240000003243 Thuja occidentalis Species 0.000 description 1
- 235000008109 Thuja occidentalis Nutrition 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 235000007423 Tolu balsam tree Nutrition 0.000 description 1
- 244000007731 Tolu balsam tree Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 229910000771 Vitallium Inorganic materials 0.000 description 1
- WAIPAZQMEIHHTJ-UHFFFAOYSA-N [Cr].[Co] Chemical compound [Cr].[Co] WAIPAZQMEIHHTJ-UHFFFAOYSA-N 0.000 description 1
- YJZATOSJMRIRIW-UHFFFAOYSA-N [Ir]=O Chemical class [Ir]=O YJZATOSJMRIRIW-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- HZEWFHLRYVTOIW-UHFFFAOYSA-N [Ti].[Ni] Chemical compound [Ti].[Ni] HZEWFHLRYVTOIW-UHFFFAOYSA-N 0.000 description 1
- NBVZMBLJRHUOJR-UHFFFAOYSA-N [amino-[4-[6-[4-[amino(azaniumylidene)methyl]phenoxy]hexoxy]phenyl]methylidene]azanium;2-hydroxyethanesulfonate Chemical compound OCCS(O)(=O)=O.OCCS(O)(=O)=O.C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 NBVZMBLJRHUOJR-UHFFFAOYSA-N 0.000 description 1
- KXBFLNPZHXDQLV-UHFFFAOYSA-N [cyclohexyl(diisocyanato)methyl]cyclohexane Chemical compound C1CCCCC1C(N=C=O)(N=C=O)C1CCCCC1 KXBFLNPZHXDQLV-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000013466 adhesive and sealant Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000010617 anise oil Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 238000002802 antimicrobial activity assay Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000004760 aramid Substances 0.000 description 1
- 239000010692 aromatic oil Substances 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000010620 bay oil Substances 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229940119201 cedar leaf oil Drugs 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940031956 chlorothymol Drugs 0.000 description 1
- 239000000788 chromium alloy Substances 0.000 description 1
- SZMZREIADCOWQA-UHFFFAOYSA-N chromium cobalt nickel Chemical compound [Cr].[Co].[Ni] SZMZREIADCOWQA-UHFFFAOYSA-N 0.000 description 1
- UOUJSJZBMCDAEU-UHFFFAOYSA-N chromium(3+);oxygen(2-) Chemical class [O-2].[O-2].[O-2].[Cr+3].[Cr+3] UOUJSJZBMCDAEU-UHFFFAOYSA-N 0.000 description 1
- AHICWQREWHDHHF-UHFFFAOYSA-N chromium;cobalt;iron;manganese;methane;molybdenum;nickel;silicon;tungsten Chemical compound C.[Si].[Cr].[Mn].[Fe].[Co].[Ni].[Mo].[W] AHICWQREWHDHHF-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- BJIOGJUNALELMI-ARJAWSKDSA-N cis-isoeugenol Chemical compound COC1=CC(\C=C/C)=CC=C1O BJIOGJUNALELMI-ARJAWSKDSA-N 0.000 description 1
- 239000010632 citronella oil Substances 0.000 description 1
- 239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
- 229910000428 cobalt oxide Inorganic materials 0.000 description 1
- IVMYJDGYRUAWML-UHFFFAOYSA-N cobalt(ii) oxide Chemical compound [Co]=O IVMYJDGYRUAWML-UHFFFAOYSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 239000004053 dental implant Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- DDXLVDQZPFLQMZ-UHFFFAOYSA-M dodecyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCCCCCCCCCCC[N+](C)(C)C DDXLVDQZPFLQMZ-UHFFFAOYSA-M 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229910000701 elgiloys (Co-Cr-Ni Alloy) Inorganic materials 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000002828 fuel tank Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960001867 guaiacol Drugs 0.000 description 1
- 235000019382 gum benzoic Nutrition 0.000 description 1
- WIHZLLGSGQNAGK-UHFFFAOYSA-N hafnium(4+);oxygen(2-) Chemical class [O-2].[O-2].[Hf+4] WIHZLLGSGQNAGK-UHFFFAOYSA-N 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 229960001715 hexamidine isethionate Drugs 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 229960004867 hexetidine Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910000457 iridium oxide Inorganic materials 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical class C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 239000001102 lavandula vera Substances 0.000 description 1
- 235000018219 lavender Nutrition 0.000 description 1
- 239000010501 lemon oil Substances 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 150000001247 metal acetylides Chemical class 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 239000002082 metal nanoparticle Substances 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002285 methylbenzethonium chloride Drugs 0.000 description 1
- 229940116837 methyleugenol Drugs 0.000 description 1
- PRHTXAOWJQTLBO-UHFFFAOYSA-N methyleugenol Natural products COC1=CC=C(C(C)=C)C=C1OC PRHTXAOWJQTLBO-UHFFFAOYSA-N 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000008164 mustard oil Substances 0.000 description 1
- 239000001673 myroxylon balsanum l. absolute Substances 0.000 description 1
- 239000011858 nanopowder Substances 0.000 description 1
- 229920003052 natural elastomer Polymers 0.000 description 1
- 229920001194 natural rubber Polymers 0.000 description 1
- 229910000480 nickel oxide Inorganic materials 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 150000004767 nitrides Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- IOQPZZOEVPZRBK-UHFFFAOYSA-N octan-1-amine Chemical compound CCCCCCCCN IOQPZZOEVPZRBK-UHFFFAOYSA-N 0.000 description 1
- 229960001774 octenidine Drugs 0.000 description 1
- SMGTYJPMKXNQFY-UHFFFAOYSA-N octenidine dihydrochloride Chemical compound Cl.Cl.C1=CC(=NCCCCCCCC)C=CN1CCCCCCCCCCN1C=CC(=NCCCCCCCC)C=C1 SMGTYJPMKXNQFY-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 1
- SOQBVABWOPYFQZ-UHFFFAOYSA-N oxygen(2-);titanium(4+) Chemical class [O-2].[O-2].[Ti+4] SOQBVABWOPYFQZ-UHFFFAOYSA-N 0.000 description 1
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical class [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 244000000018 pandemic pathogen Species 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- 239000005011 phenolic resin Substances 0.000 description 1
- 229960000969 phenyl salicylate Drugs 0.000 description 1
- 239000010665 pine oil Substances 0.000 description 1
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 description 1
- 229920000052 poly(p-xylylene) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000903 polyhydroxyalkanoate Polymers 0.000 description 1
- 229920000307 polymer substrate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940078492 ppg-17 Drugs 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- 239000010672 sassafras oil Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229910001285 shape-memory alloy Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940087124 spike lavender oil Drugs 0.000 description 1
- 229920006301 statistical copolymer Polymers 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920003051 synthetic elastomer Polymers 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 1
- 239000010678 thyme oil Substances 0.000 description 1
- XOLBLPGZBRYERU-UHFFFAOYSA-N tin dioxide Chemical compound O=[Sn]=O XOLBLPGZBRYERU-UHFFFAOYSA-N 0.000 description 1
- 229910001887 tin oxide Inorganic materials 0.000 description 1
- 229940088660 tolu balsam Drugs 0.000 description 1
- BJIOGJUNALELMI-UHFFFAOYSA-N trans-isoeugenol Natural products COC1=CC(C=CC)=CC=C1O BJIOGJUNALELMI-UHFFFAOYSA-N 0.000 description 1
- SRPWOOOHEPICQU-UHFFFAOYSA-N trimellitic anhydride Chemical compound OC(=O)C1=CC=C2C(=O)OC(=O)C2=C1 SRPWOOOHEPICQU-UHFFFAOYSA-N 0.000 description 1
- 150000004788 tropolones Chemical class 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- DCSCXTJOXBUFGB-UHFFFAOYSA-N verbenone Natural products CC1=CC(=O)C2C(C)(C)C1C2 DCSCXTJOXBUFGB-UHFFFAOYSA-N 0.000 description 1
- 229920001567 vinyl ester resin Polymers 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 239000000602 vitallium Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000004065 wastewater treatment Methods 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 229910001928 zirconium oxide Inorganic materials 0.000 description 1
- 229930007845 β-thujaplicin Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D101/00—Coating compositions based on cellulose, modified cellulose, or cellulose derivatives
- C09D101/08—Cellulose derivatives
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/16—Antifouling paints; Underwater paints
- C09D5/1606—Antifouling paints; Underwater paints characterised by the anti-fouling agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/29—Titanium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/347—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/88—Polyamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q3/00—Manicure or pedicure preparations
- A61Q3/02—Nail coatings
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K9/00—Use of pretreated ingredients
- C08K9/02—Ingredients treated with inorganic substances
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
- C08L77/04—Polyamides derived from alpha-amino carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L79/00—Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen with or without oxygen or carbon only, not provided for in groups C08L61/00 - C08L77/00
- C08L79/02—Polyamines
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D177/00—Coating compositions based on polyamides obtained by reactions forming a carboxylic amide link in the main chain; Coating compositions based on derivatives of such polymers
- C09D177/04—Polyamides derived from alpha-amino carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D179/00—Coating compositions based on macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing nitrogen, with or without oxygen, or carbon only, not provided for in groups C09D161/00 - C09D177/00
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D191/00—Coating compositions based on oils, fats or waxes; Coating compositions based on derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/14—Paints containing biocides, e.g. fungicides, insecticides or pesticides
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
- C09D5/00—Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
- C09D5/16—Antifouling paints; Underwater paints
- C09D5/1606—Antifouling paints; Underwater paints characterised by the anti-fouling agent
- C09D5/1612—Non-macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K11/00—Use of ingredients of unknown constitution, e.g. undefined reaction products
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/02—Elements
- C08K3/08—Metals
- C08K2003/085—Copper
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/18—Oxygen-containing compounds, e.g. metal carbonyls
- C08K3/20—Oxides; Hydroxides
- C08K3/22—Oxides; Hydroxides of metals
- C08K2003/2237—Oxides; Hydroxides of metals of titanium
- C08K2003/2241—Titanium dioxide
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/18—Oxygen-containing compounds, e.g. metal carbonyls
- C08K3/20—Oxides; Hydroxides
- C08K3/22—Oxides; Hydroxides of metals
- C08K2003/2248—Oxides; Hydroxides of metals of copper
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/002—Physical properties
- C08K2201/003—Additives being defined by their diameter
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/007—Fragrance additive
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/011—Nanostructured additives
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/02—Elements
- C08K3/08—Metals
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/18—Oxygen-containing compounds, e.g. metal carbonyls
- C08K3/20—Oxides; Hydroxides
- C08K3/22—Oxides; Hydroxides of metals
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/05—Alcohols; Metal alcoholates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/07—Aldehydes; Ketones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/13—Phenols; Phenolates
Definitions
- compositions which may be formulated as coating compositions.
- the compositions may be used as antipathogenic compositions, antipathogenic films, or antipathogenic coatings.
- the compositions disclosed herein may be applied across multiple industries including, but not limited to: infrastructure, construction, food processing/packaging, manufacturing and/or medical applications.
- COVID-19 has irreversibly changed the way we live highlighting the risk of disease and societal impacts caused by respiratory viruses such as SARS-CoV-2. Furthermore, with the growth of antimicrobial resistance, society needs innovative solutions to ensure that people can continue to live safe and healthy lives. In the absence of drugs or vaccines, it is human behaviour that becomes the primary weapon to control the spread of disease. Prevention of infection through inactivation of pathogens on surfaces is crucial to ongoing control of disease transmission. It will also play an important role in the restoration of business confidence and reducing the risk to public health due to surface contamination.
- Routine sanitisation and disinfection of surfaces to reduce the spread of pathogens, for example hospital-related bacteria have been implemented.
- increased use of common disinfectants products containing quaternary ammonium compounds, hydrogen peroxide, bleach and alcohols may cause detrimental effects on human health and the environment.
- the repeated application of disinfectant processes may be labour intensive, with efficacy waning over a limited period, such as over minutes as opposed to hours.
- the costs associated with routine cleaning of the surfaces are high and may not guarantee their complete decontamination.
- Anti-infective surfaces where antipathogenic agents (such as antiviral/antibacterial agents) are released over time would reduce the cost of routine sanitisation by decreasing the survival of pathogens for longer periods.
- SARS-CoV-2 is one of many pathogens causing problems around the globe.
- the synthesis and application of materials and coatings that could assist in reducing or eliminating the presence of one or more pathogens could potentially reduce the number of people being affected by infections, and potentially prevent serious illnesses.
- compositions capable of forming an antipathogenic film or coating comprising: (i) at least one essential oil; (ii) at least one metal species; and (iii) at least one cationic species.
- Disclosed herein is a method of controlling, preventing and/or reducing the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof, the method comprising applying a composition as defined herein, to at least a portion of a surface of an article.
- a composition as defined herein to control, prevent and/or reduce the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
- compositions as defined herein in the formation of an antipathogenic composition, film or coating.
- compositions as defined herein as an antifouling composition, film or coating.
- composition comprising a combination of compounds selected from: (i) at least one essential oil; (ii) at least one metal species; and (iii) at least one cationic species.
- the composition may also use a polymer to provide increased antipathogenic activity (for example antibacterial, antiviral and/or antifungal activity,) potentially via a synergistic combination of combined compounds, based on the pathogen or groups of pathogens that need to be controlled or eliminated.
- pathogen refers to a microorganism that can potentially cause a disease or illness in an organism, and includes: a virus, bacterium, protozoan, prion, viroid, or fungus.
- Antipathogenic refers to molecules and/or compositions that kill and/or prevent fouling by microorganisms including: bacteria, yeast, fungi, mycoplasma, and viruses.
- antipathogenic activity is defined as an activity that kills or inhibits the growth of microorganisms including, but not limited to bacteria, viruses, parasites, and fungi.
- antipathogenic encompasses, the antipathogenic/antipathogenic agent/antipathogenic compound and, where permitted, all derivatives, isomeric forms, racemates, amorphous forms, crystalline forms, solvates, acceptable salts, solvates of said salts, and prodrugs thereof in isolation from one another as well as mixtures.
- the composition may comprise a polymer base.
- the polymer base may provide a medium that allows the composition to adhere to at least a portion of an article, comprising or composed of a material, such as wood, metal and/or plastics.
- the polymer base may also act as a vehicle for the components of the composition (for example (i) at least one essential oil; (ii) at least one metal species; and (iii) at least one cationic species), to move through the article (for example a substrate) and onto one or more surfaces.
- the polymer base may comprise one or more film formers.
- the components of a composition described herein are activated to control, reduce and/or eliminate the concentration of at least one pathogen, once the polymer base is in contact with an aqueous solution or solvent.
- the aqueous solution may, for example, be the sweat of a person contacting the composition, such as from the hand of a subject contacting the composition disposed on an article, such as a door handle.
- the composition may therefore have a “start stop” mechanism, wherein the composition controls, reduces and/or eliminates one or more pathogens whilst an appropriate concentration of water and/or an appropriate solvent is provided. This mode of action may preserve the longevity of the composition, and in one embodiment, extend the antipathogenic activity of the composition.
- This mechanism may also minimise the overuse of antipathogenic compounds, when not necessary, reducing the chance of developing any associated resistance to one or more pathogens, and/or its overall environmental impact.
- the antipathogenic compounds contained in a composition disposed on an article become mobile and active when wiped down by a wet cloth during normal sanitation process.
- compositions may also be able to be tailored for specific applications and/or the materials that the compositions are to be applied. For example, the type and concentration of the components.
- the thickness of any composition, for example a composition comprising a polymer base may be controlled, for example by applying multiple layers of the same composition after an earlier applied composition has been applied. This may be appropriate in manufacturing settings, wherein equipment can be coated with the antipathogenic composition, film or coating, to create a protective barrier when in contact with disease causing materials.
- composition may be tailored using different polymer bases.
- polymer bases can be in the form of commercially available products.
- a paint formulation used in an air conditioning unit may comprise the antipathogenic formulation (being i) at least one essential oil, ii) at least one metal species, and iii) at least one cationic species), thereby creating a purified surface or air flow.
- the composition may also be tailored so numerous application techniques are viable, the composition could be applied as a liquid, a paste or aerosol.
- the composition may be sprayed onto a surface through a manual mechanism such as a spray bottle activated by a hand trigger. In large-scale manufacturing settings, it may also be spray coated by a high-pressure nozzle onto products before they are sent to market. Large scale mixing processes of the composition into the bulk of a material may also be used for high volume manufacturing.
- the components of the composition can be tailored to target specific pathogens or groups of pathogens.
- the composition may be tailored with a group of compounds displaying the highest efficacy for one or more pathogens. During a pandemic, or outbreak, the composition may be adapted to provide efficacy for the pandemic pathogen, and potentially adapted again to account for variants of said pathogens.
- the composition may be tailored so that it can be removed with a solvent, optionally removed to re-apply a fresh amount of the composition after an appropriate period of use/application has elapsed. This may be useful in construction mould remediation settings, where continued application of the composition may create layers too thick for purpose. The removability of this layer allows a fresh coat to be added without a build-up of previous coatings.
- compositions described herein may be used to potentially reduce the risk for acquiring infectious diseases through surface transmission, for example in environments where care is provided to vulnerable residents such as aged care facilities or hospitals, as well as in high-density environments.
- a single application of a composition described herein may control, reduce and/or eliminate one or more bacteria, viruses and/or fungi.
- the composition may be used on medical devices to be implanted inside the human body.
- the antipathogenic composition, film or coating has a biocompatible nature, it may be used on medical devices like catheters that are inserted into the body, which require a high level of antipathogenic activity over long periods of time.
- compositions described herein may display efficacy for an extended period, for example the compositions may display an efficacy against one or more pathogens or microbes for 30 or more days.
- the compositions may display an efficacy of 30 or more days during continuous use during this period, for example without the need for a further application of the same or different composition.
- An instance of this is that it may be used in the food industry for packaging of agricultural food products to be shipped to consumers.
- an anti-pathogenic layer on food packaging that continuously kills for multiple days may allow it to reduce mould growth and extend the shelf-life of food.
- compositions described herein may provide advantages such as saving on costs for a business or an organisation by assisting in the simplification of sanitation processes, for example by relieving staff of the need to disinfect as often. This may save on the amount of hours and material needed to disinfect commonly touched surfaces and the costs associated with this time and effort.
- the composition may prophylactically kill pathogens, reducing the need for other surfaces to be as frequently disinfected via other means. For example, from the application of a chemical or the use of wipes. This may save on the amount of hours and material needed to disinfect commonly touched surfaces, reducing excess waste and improving its environmental friendliness, for example in high-density environments.
- compositions may provide higher public safety outcomes. By reducing the amount of hours for disinfection, this may reduce the risk for parties such cleaners acquiring infectious diseases from areas such as high-density environments.
- the compositions herein may therefore provide a means to improve safety, whilst also potentially saving on labour intensive cleaning processes.
- Figure 1 Schematic of the antipathogen coating containing the three- components including an essential oil, a metal compound and a cationic polymer.
- Figure 2 Activity of different compounds evaluated using the zone of inhibition test against Staph, aureus. The compounds tested were: A) polymeric formulation (control); B) AgCu nanoparticles; C) copper oxide (Cu(II)O); D) cinnamaldehyde; E) carvacrol; F) tea tree oil; G) s-poly-L-lysinc (a-PL); and H) PHMB.
- Figure 3 Antibacterial activity of different compounds evaluated using the zone of inhibition test against P. aeruginosa.
- the compounds tested were: A) polymeric formulation (control); B) AgCu nanoparticles; C) copper oxide (Cu(II)O); D) cinnamaldehyde; E) carvacrol; F) tea tree oil; G) a-PL; and H) PHMB.
- Figure 4 Graph of crystal violet test of biofdm mass vs combination of two antipathogenic compounds against Staph, aureus.
- Figure 5 Graph of crystal violet test of biofdm mass vs combination of two antipathogenic compounds against P. aeruginosa.
- Figure 6 Graph of biofdm experiment using aluminium substrates. Logarithmic reduction of the cfu/mL obtained from the viable counting of the samples. Both Staph, aureus and P. aeruginosa were evaluated.
- Figure 7 Pictures of 96 well plate biofdm experiment using three components combination.
- Combination 1 A 1-2) control samples - polymeric fdm; Bl-2) Ag-Cu/Cinnamaldchydc/s-PL.
- Combination 2 Cl-2) Ag- Cu/Cinnamaldehyde/PHMB; DI -2) Cu(II)O/Cinnamaldehyde/8-PL; El -2) Cu(II)O/Cinnamaldehyde/PHMB .
- Figure 8 - Graph of Log (cfu/mL) vs
- Figure 9 Graph of antiviral infectivity assay for a group of antipathogenic components vs OC43.
- FIG. 10 Graphs of antiviral infectivity assay for a group of antipathogenic components vs RV-A1 on A - a logarithmic scale; and B - a linear scale.
- first Unless otherwise indicated, the terms “first,” “second,” etc. are used herein merely as labels, and are not intended to impose ordinal, positional, or hierarchical requirements on the items to which these terms refer. Moreover, reference to a “second” item does not require or preclude the existence of lower-numbered item (e.g., a “first” item) and/or a higher-numbered item (e.g., a “third” item).
- the phrase “at least one of’ or “one or more of’ when used with a list of items, means different combinations of one or more of the listed items may be used and only one of the items in the list may be needed.
- the item may be a particular object, thing, or category.
- “at least one of’ means any combination of items or number of items may be used from the list, but not all of the items in the list may be required.
- “at least one of item A, item B, and item C” may mean item A; item A and item B; item B; item A, item B, and item C; or item B and item C.
- “at least one of item A, item B, and item C” may mean, for example and without limitation, two of item A, one of item B, and ten of item C; four of item B and seven of item C; or some other suitable combination.
- range format is included for convenience and should not be interpreted as an inflexible limitation on the scope of the present disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range, unless specifically indicated. For example, description of a range such as from 1 to 5 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 5, from 3 to 5 etc., as well as individual and partial numbers within the recited range, for example, 1, 2, 3, 4, 4.5, and 5, unless where integers are required or implicit from context. This applies regardless of the breadth of the disclosed range. Where specific values are required, these will be indicated in the specification.
- the term “consisting essentially of” is intended to exclude elements which would materially affect the properties of the claimed composition, although may include elements that do not materially affect properties.
- the terms “comprising”, “comprise” and “comprises” herein are intended to be optionally substitutable with the terms “consisting essentially of, “consist essentially of, “consists essentially of, “consisting of, “consist of and “consists of, respectively, in every instance.
- Article refers to an object or substrate, comprising one or more materials, on which a composition as described herein, optionally in the form of a coating, is applied, or is incorporate on or within, or on which the composition is immobilised.
- coating refers to any temporary, semi-permanent or permanent layer, or layers, treating or covering a surface, or a portion thereof of an article.
- the coating may be a chemical modification of at least a portion of the underlying article or may involve the addition of new materials to at least a portion of an article. It includes any increase in thickness to the substrate or change in surface chemical composition of at least a portion of the article.
- a coating may be applied as a liquid, for example as a paint or spray, and solidified into a solid coating.
- the coating may be applied as and/or comprise a single layer of a composition (and may take the form of a film), or the coating may be applied as and/or comprise a plurality of layers of one or more compositions.
- the plurality of layers may be the same or comprise different compositions.
- the coating comprises a single composition.
- the coating may be contiguous over a surface of an article, or may be present on at least a portion of a surface of an article.
- film refers to a material, including a coating, deposited or used in thin sections or layer form.
- the layer may be contiguous over a surface of an article, or may be present on at least a portion of a surface of an article.
- % may relate to v/v, w/w or w/v, unless specifically described.
- an “essential oil” may comprise any one or more oils, said oils which may be water insoluble, or substantially water-insoluble.
- One or more essential oils may be soluble in one or more of: an alcohol, an ether, an organic solvent, such as a hydrocarbon, and mixtures thereof.
- the solubility of one or more essential oil may be less than about 5, 4, 3, 2 1, or 0.5 % by weight in water at 25 °C or, optionally, less than about 0.1%.
- the one or more essential oils may be volatile aromatic oils which may be synthetic or may be derived from plants by distillation, expression or extraction, and may carry the odour or flavour of the plant from which they are obtained.
- One or more essential oils may provide antiseptic activity.
- essential oils include but are not limited to: citra, thymol, menthol, methyl salicylate (wintergreen oil), eucalyptol, carvacrol, camphor, anethole, carvone, eugenol, isoeugenol, limonene, osimen, n-decyl alcohol, citronel, a-salpineol, methyl acetate, cloves, citronellyl acetate, methyl eugenol, cineol, linalool, ethyl linalaol, safrole, vanillin, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cinnamon oil, pimento oil, laurel oil, cedar leaf oil, gerianol, verbenone, anise oil, bay oil, benzaldehyde, bergamot oil, bitter almond, chlorothymol, cinna
- the essential oils are selected from the group consisting of thymol ((CHs CHCeHs CH OH, also known as isopropyl-m-cresol), eucalyptol (CioHisO, also known as cineol), menthol (CHsCeH ⁇ Cs ⁇ OH), also known as hexahydrothymol), methyl salicylate (CeEEOHCOOCHs, also known as wintergreen oil), isomers of each of these compounds, and combinations of two or more thereof.
- the present disclosure considers salts of essential oils or components of essential oils such as the salts of monoterpenoid compounds.
- An example of a monoterpenoid compound is thymol.
- the present disclosure contemplates salts of thymol as acceptable salts.
- an acceptable salt of thymol is the berberine ammonium cation salt of thymol and, vice versa
- an acceptable salt of berberine is the thymol phenolate salt of berberine. It will be recognised that such a salt may display a combination of the biological activity possessed by the berberine ammonium cation and the biological activity possessed by the thymol phenolate counter anion.
- composition which may be used for forming an antipathogenic composition, fdm or coating, the composition comprising:
- the composition comprises at least one essential oil.
- the at least one essential oil may be or an extract of: cloves, thyme, fennel, caraway, peppermint, lemon myrtle, tea tree, thymol, carvacrol, eugenol, menthol, terpineol, carvone, citral, arborvitae, Asteraceae, Bergamot, cajuput, Cassia, Cedarwood, Cinnamon, Citron, clary sage, coriander, Eucalyptis, fennel, frankincense, lavender, lemon, lemongrass, Manuka, oregano, Perilla, rosemary, white fir, wild orange, wintergreen, ylang, or mixtures thereof.
- the at least one essential oil may be selected from: cinnamaldehyde, tea tree oil, carvacrol, or mixtures thereof.
- one or more essential oils may be present in a range of about 0.05% v/v to about 10% v/v, or about 0.1 % v/v to about 5% v/v , or about 0.5 % v/v to about 3% v/v ; or in a range of about 0.05% w/v to about 10% w/v, or about 0.1 % w/v to about 5% w/v, or about 0.5% w/v to about 3% w/v; or in a range of about 0.05% w/w to about 10% w/w, or about 0.1% w/w to about 5% w/w, or about 0.5% w/w to about 3% w/w.
- one or more essential oils may be present in an amount of about, or at least about: 0.05% v/v, 0.1%, v/v, 0.5% v/v, 1% v/v, 1.5% v/v, 2% v/v, 2.5% v/v, 3% v/v, 3.5% v/v, 4% v/v, 4.5% v/v, 5% v/v, 5.5% v/v, 6% v/v, 6.5% v/v, 7% v/v, 7.5% v/v, 8% v/v, 8.5% v/v, 9% v/v, 9.5% v/v, or 10% v/v.
- one or more essential oils may be present in an amount of about, or at least about: 0.05% w/v, 0.1%, w/v, 0.5% w/v, 1% w/v, 1.5% w/v, 2% w/v, 2.5% w/v, 3% w/v, 3.5% w/v, 4% w/v, 4.5% w/v, 5% w/v, 5.5% w/v, 6% w/v, 6.5% w/v, 7% w/v, 7.5% w/v, 8% w/v, 8.5% w/v, 9% w/v, 9.5% w/v, or 10% w/v.
- one or more essential oils may be present in an amount of about, or at least about: 0.05% w/w, 0.1%, w/w, 0.5% w/w, 1% w/w, 1.5% w/w, 2% w/w, 2.5% w/w, 3% w/w, 3.5% w/w, 4% w/w, 4.5% w/w, 5% w/w, 5.5% w/w, 6% w/w, 6.5% w/w, 7% w/w, 7.5% w/w, 8% w/w, 8.5% w/w, 9% w/w, 9.5% w/w, or 10% w/w.
- composition comprises at least one metal species.
- the at least one metal species comprises at least one elemental metal.
- At least one metal species, or all the metal species may be replaced with at least one transition element, for example selenium, or a salt, oxide or complex thereof.
- the metal species may be or comprise one or metals (for example as a mixture or elements and/or compounds, or alloys).
- the at least one metal species comprises at least one metal selected from: copper, silver, titanium aluminium, cobalt, gold, lead, magnesium, molybdenum, nickel, tin, zinc, zirconium, compounds thereof, mixtures thereof, and alloys thereof.
- at least one metal species is an oxide. Examples of oxides include, but are not limited to: copper oxide, titanium oxide, aluminium oxide, cobalt oxide, magnesium oxide, nickel oxide, tin oxide, zinc oxide and mixtures thereof.
- the at least one metal species is a salt.
- the at least one metal species is a complex.
- At least one metal species is a mixture of metals.
- At least one metal species is an alloy.
- the at least one metal species may be used in any form known in the art.
- the at least one metal species may be in the form of a powder.
- the at least one metal species may be in the form of a particle.
- the at least one metal species may be colloidal.
- the at least one metal species may be in the form of a coated particle, for example a metal particle comprising a mixture of metals, for example silver and copper.
- the at least one metal species may comprise particles on the nanoscale.
- the at least one metal species may be a particle with a mean diameter of about, or at least about: 50 nm to about 100 nm.
- the at least one metal species may have a mean diameter of about, or at least about: 1 nm, 5 nm, 10, nm, 15 nm, 20 nm, 25 nm, 30 nm, 35 nm, 40 nm, 45 nm, 50 nm; 55 nm; 60 nm; 65 nm; 70 nm; 75 nm; 80 nm; 85 nm; 90 nm; 95 nm; or 100 nm.
- one or more metal species may be present in a range of about 0.05% v/v to about 10% v/v, or about 0.1 % v/v to about 5% v/v , or about 0.5 % v/v to about 3% v/v ; or in a range of about 0.05% w/v to about 10% w/v, or about 0.1 % w/v to about 5% w/v, or about 0.5% w/v to about 3% w/v; or in a range of about 0.05% w/w to about 10% w/w, or about 0.1% w/w to about 5% w/w, or about 0.5% w/w to about 3% w/w.
- one or more metal species may be present in an amount of about, or at least about: 0.05% v/v, 0.1%, v/v, 0.5% v/v, 1% v/v, 1.5% v/v, 2% v/v, 2.5% v/v, 3% v/v, 3.5% v/v, 4% v/v, 4.5% v/v, 5% v/v, 5.5% v/v, 6% v/v, 6.5% v/v, 7% v/v, 7.5% v/v, 8% v/v, 8.5% v/v, 9% v/v, 9.5% v/v, or 10% v/v.
- one or more metal species may be present in an amount of about, or at least about: 0.05% w/v, 0.1%, w/v, 0.5% w/v, 1% w/v, 1.5% w/v, 2% w/v, 2.5% w/v, 3% w/v, 3.5% w/v, 4% w/v, 4.5% w/v, 5% w/v, 5.5% w/v, 6% w/v, 6.5% w/v, 7% w/v, 7.5% w/v, 8% w/v, 8.5% w/v, 9% w/v, 9.5% w/v, or 10% w/v.
- one or more metal species may be present in an amount of about, or at least about: 0.05% w/w, 0.1%, w/w, 0.5% w/w, l% w/w, 1.5% w/w, 2% w/w, 2.5% w/w, 3% w/w, 3.5% w/w, 4% w/w, 4.5% w/w, 5% w/w, 5.5% w/w, 6% w/w, 6.5% w/w, 7% w/w, 7.5% w/w, 8% w/w, 8.5% w/w, 9% w/w, 9.5% w/w, or 10% w/w.
- composition comprises at least one cationic species.
- cationic species include, but are not limited to:
- quaternary ammonium compounds such as those in which one or two of the substituents on the quaternary nitrogen has from 8 to 20, for example from 10 to 18 carbon atoms, such as an alkyl group, which may optionally be interrupted by an amide, ester, oxygen, sulfur, or heterocyclic ring, while the remaining substituents have a lower number of carbon atoms, for instance from 1 to 7, and are optionally alkyl, for instance methyl or ethyl, or benzyl.
- Examples of such compounds include benzalkonium chloride, dodecyl trimethyl ammonium chloride, benzyl dimethyl stearyl ammonium chloride, hexadecyltrimethyl ammonium bromide, benzethonium chloride (diisobutyl phenoxyethoxyethyl dimethyl benzyl ammonium chloride) and methyl benzethonium chloride;
- pyrimidine derivatives such as hexetidine (5-amino-l,3-bis(2-ethylhexyl)- 5 -methyl -hexahydropyrimidine) ;
- amidine derivatives such as hexamidine isethionate (4,4'-diamidino-a,co- diphenoxy-hexane isethionate);
- guanides for example, mono-biguanides such as p- chlorobenzylbiguanide and N'(4-chlorobenzyl)-N" -(2,4-dichlorobenzyl) biguanide, poly(biguanides) such as polyhexamethylene biguanide hydrochloride; and/or
- one or more cationic species may be present in a range of about 0.05% v/v to about 10% v/v, or about 0.1 % v/v to about 5% v/v , or about 0.5 % v/v to about 3% v/v ; or in a range of about 0.05% w/v to about 10% w/v, or about 0.1 % w/v to about 5% w/v, or about 0.5% w/v to about 3% w/v; or in a range of about 0.05% w/w to about 10% w/w, or about 0.1% w/w to about 5% w/w, or about 0.5% w/w to about 3% w/w.
- one or cationic species may be present in an amount of about, less than about, or at least about: 0.05% v/v, 0.1%, v/v, 0.5% v/v, 1% v/v, 1.5% v/v, 2% v/v, 2.5% v/v, 3% v/v, 3.5% v/v, 4% v/v, 4.5% v/v, 5% v/v, 5.5% v/v, 6% v/v, 6.5% v/v, 7% v/v, 7.5% v/v, 8% v/v, 8.5% v/v, 9% v/v, 9.5% v/v, or 10% v/v.
- one or more cationic species may be present in an amount of about, less than about, or at least about: 0.05% w/v, 0.1%, w/v, 0.5% w/v, 1% w/v, 1.5% w/v, 2% w/v, 2.5% w/v, 3% w/v, 3.5% w/v, 4% w/v, 4.5% w/v, 5% w/v, 5.5% w/v, 6% w/v, 6.5% w/v, 7% w/v, 7.5% w/v, 8% w/v, 8.5% w/v, 9% w/v, 9.5% w/v, or 10% w/v.
- one or more cationic species may be present in an amount of about, less than about, or at least about: 0.05% w/w, 0. 1%, w/w, 0.5% w/w, 1% w/w, 1.5% w/w, 2% w/w, 2.5% w/w, 3% w/w, 3.5% w/w, 4% w/w, 4.5% w/w, 5% w/w, 5.5% w/w, 6% w/w, 6.5% w/w, 7% w/w, 7.5% w/w, 8% w/w, 8.5% w/w, 9% w/w, 9.5% w/w, or 10% w/w.
- the cationic species is a cationic polymer.
- the cationic polymer may be a homopolymer or a copolymer. In one embodiment the cationic polymer is a homopolymer. In another embodiment the cationic polymer is a copolymer, for example a statistical, gradient or block copolymer.
- the cationic polymer may comprise one or more monomers selected from: lysine, hexamethylene guanidine, imidazolium, piperidinium, quaternary ammonium, ethylenimine, 2-dimethy(aminoethyl) methacrylate, chitosan, and mixtures thereof.
- a polymer of lysine is used.
- lysine polymers include polymers of L-lysine and D-lysine.
- the lysine polymers may be in the a or s form.
- the lysine polymer may be: a-poly(L-lysine), a-poly(D-lysine), 8-poly (L-lysine), e-poly(D-lysine), or a mixture thereof.
- the cationic polymer is 8- poly (L-lysine).
- the cationic polymer may be a salt known in the art.
- the cationic polymer may be a salt selected from: a halo salt such as a chloride salt, a sulfate salt, a nitrate salt, or a mixture thereof.
- one or more cation polymers may be present in a range of about 0.05% v/v to about 10% v/v, or about 0.1 % v/v to about 5% v/v , or about 0.5 % v/v to about 3% v/v ; or in a range of about 0.05% w/v to about 10% w/v, or about 0.1 % w/v to about 5% w/v, or about 0.5% w/v to about 3% w/v; or in a range of about 0.05% w/w to about 10% w/w, or about 0.1% w/w to about 5% w/w, or about 0.5% w/w to about 3% w/w.
- one or cationic polymers may be present in an amount of about, less than about, or at least about: 0.5% v/v, 1% v/v, 1.5% v/v, 2% v/v, 2.5% v/v, 3% v/v, 3.5% v/v, 4% v/v, 4.5% v/v, 5% v/v, 5.5% v/v, 6% v/v, 6.5% v/v, 7% v/v, 7.5% v/v, 8% v/v, 8.5% v/v, 9% v/v, 9.5% v/v, or 10% v/v.
- one or more cationic polymers may be present in an amount of about, less than about, or at least about: 0.5% w/v, 1% w/v, 1.5% w/v, 2% w/v, 2.5% w/v, 3% w/v, 3.5% w/v, 4% w/v, 4.5% w/v, 5% w/v, 5.5% w/v, 6% w/v, 6.5% w/v, 7% w/v, 7.5% w/v, 8% w/v, 8.5% w/v, 9% w/v, 9.5% w/v, or 10% w/v.
- one or more cationic polymers may be present in an amount of about, less than about, or at least about: 0.5% w/w, l% w/w, 1.5% w/w, 2% w/w, 2.5% w/w, 3% w/w, 3.5% w/w, 4% w/w, 4.5% w/w, 5% w/w, 5.5% w/w, 6% w/w, 6.5% w/w, 7% w/w, 7.5% w/w, 8% w/w, 8.5% w/w, 9% w/w, 9.5% w/w, or 10% w/w.
- the composition may further comprise an organic solvent.
- the organic solvent may be selected from: alkylacetates, arylacetates, alcohols (including primary, secondary and/or tertiary alcohols), carboxylic acids, ethers, ketones, alkanes, hydrocarbons (aliphatic, nitrated and chlorinated hydrocarbons), amine, esters, terpenoids, and mixtures thereof.
- the organic solvent may be selected from: butyl acetate, ethyl acetate, ethanol, methanol, isopropanol, diacetone alcohol, acetone, ethanol, acetone-water mixtures, propanol, butanol, tert-butyl alcohol, diethyl ether, tetrahydrofuran, methyl ethyl ketone, benzyl alcohol, ethyl acetate-ethanol mixtures, glycol mixtures, acetic acid, lactic acid, propionic acid, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, ethylene glycol butyl ether, ethylene glycol ethyl ether, ethylene glycol methyl ether, dioxane, cyclohexanone, amyl alcohol, sec-butyl alcohol, iso-butyl carbinol, diacetone alcohol, citronellol, amy
- composition described herein further comprises a polymer base.
- the polymer base may comprise one or more of: a polymer, an organic solvent, a plasticizer, a dye or pigment, an adhesive, a bulking agent, a thickening agent, emulsion polymers, and mixtures thereof.
- the polymer base comprises at least one polymer, which may be a homo polymer or a copolymer.
- the polymer is suitable for forming a fdm.
- the composition may comprise a polymer and forms a fdm after initially being applied to at least a portion of a surface on an article in a non-solid form, for example as a spray or as a liquid.
- the polymer base may comprise one or more polymers, for example: a polymer comprising cellulose, a polyurethane, polyethylene terephthalate, an epoxy resin, a vinyl ester, a phenolic polymer, an acrylic ester, an acrylate homopolymer or copolymer, a latex paint, a polyester, and mixtures thereof.
- a polymer comprising cellulose, a polyurethane, polyethylene terephthalate, an epoxy resin, a vinyl ester, a phenolic polymer, an acrylic ester, an acrylate homopolymer or copolymer, a latex paint, a polyester, and mixtures thereof.
- At least one polymer comprises a cellulose, optionally selected from one or more of: nitrocellulose, cellulose acetate, cellulose acetate butyrate, ethyl cellulose, alkyd resin, and mixtures thereof.
- the polymer base may comprise one or more organic solvents, optionally selected from: alkylacetates, arylacetates, alcohols (including primary, secondary and/or tertiary alcohols), carboxylic acids, ethers, ketones, alkanes, hydrocarbons (aliphatic, nitrated and chlorinated hydrocarbons), amine, esters, terpenoids, and mixtures thereof.
- organic solvents optionally selected from: alkylacetates, arylacetates, alcohols (including primary, secondary and/or tertiary alcohols), carboxylic acids, ethers, ketones, alkanes, hydrocarbons (aliphatic, nitrated and chlorinated hydrocarbons), amine, esters, terpenoids, and mixtures thereof.
- the organic solvent may be optionally selected from: butyl acetate, ethyl acetate, ethanol, methanol, isopropanol, diacetone alcohol, acetone, ethanol, acetone-water mixtures, propanol, butanol, tert-butyl alcohol, diethyl ether, tetrahydrofuran, methyl ethyl ketone, benzyl alcohol, ethyl acetate-ethanol mixtures, glycol mixtures, acetic acid, lactic acid, propionic acid, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, ethylene glycol butyl ether, ethylene glycol ethyl ether, ethylene glycol methyl ether, dioxane, cyclohexanone, amyl alcohol, sec-butyl alcohol, iso-butyl carbinol, diacetone alcohol, citronellol,
- the polymer base may comprise one or more plasticizers, optionally selected from: phthalates, dibutyl phthalate, a citrate, tributyl acetyl citrate, ethyl toluene sulfonamide (ethyl tosylamide), n-cyclohexyl para-toluene sulfonamide, glycerol, a glycol, glycol ethers, glycol esters, hydrogenated castor oil or an epoxidized oil, polyesters, polybutylenes, aliphatic polyurethanes (optionally with a molecular wright of about 2000 to about 5000), toluene sulfonamide urea formaldehyde, y-butyral lactone, n- butylphthalimide/isopropylphthalimide, ethylhexyl diphenyl phosphate, wool fat derivatives, chlorinated paraffins, glyceryl
- the polymer base may comprise one or more dyes known in the art and mixtures thereof.
- the polymer base may comprise one or more adhesives, optionally in the form of a polymer, optionally selected from: tosylamide-formaldehyde resin, alkyd resin or another polymer known in the art, and mixtures thereof.
- the polymer base may comprise one or more thickening agents and/or bulking agents, optionally selected from: fluorphlogopite (for example synthetic fluorphlogopite) which comprises magnesium aluminium silicate and potassium, an aluminium borosilicate, for example calcium aluminium borosilicate, stearalkonium bentonite, stearalkonium hectorite, and mixtures thereof.
- the polymer base is formulated as a nail polish.
- the composition may comprise one or more additives, for example an additive optionally selected from: iodine, benzalkonium chloride, graphene oxide, and mixtures thereof.
- an additive optionally selected from: iodine, benzalkonium chloride, graphene oxide, and mixtures thereof.
- compositions may or may not be cross-linked.
- the composition is cross-linked.
- the composition is not cross-linked.
- One potential advantage obtained from the crosslinking of a composition, film or coating is the stability of the resulting materials, for example crosslinking can reduce the solubility of the coating in comparison to similar compositions which are not crosslinked.
- the cross-linked nature of a coating may increase the chemical resistance of the composition.
- the application of a cross-linked polymer to a surface of an article may also yield a surface which has an increased heat tolerance, decreased permeability, improved abrasion resistance and/or extend the life of the article.
- the composition may be removed from an article, or portion thereof, by the application of at least one solvent optionally selected from: alkylacetates, arylacetates, alcohols (including primary, secondary and/or tertiary alcohols), carboxylic acids, ethers, ketones, alkanes, hydrocarbons (aliphatic, nitrated and chlorinated hydrocarbons), amine, esters, terpenoids, and mixtures thereof.
- at least one solvent optionally selected from: alkylacetates, arylacetates, alcohols (including primary, secondary and/or tertiary alcohols), carboxylic acids, ethers, ketones, alkanes, hydrocarbons (aliphatic, nitrated and chlorinated hydrocarbons), amine, esters, terpenoids, and mixtures thereof.
- the composition may be removed by the application of an organic solvent optionally selected from: butyl acetate, ethyl acetate, ethanol, methanol, isopropanol, diacetone alcohol, acetone, ethanol, acetone-water mixtures, propanol, butanol, tert-butyl alcohol, diethyl ether, tetrahydrofuran, methyl ethyl ketone, benzyl alcohol, ethyl acetate-ethanol mixtures, glycol mixtures, acetic acid, lactic acid, propionic acid, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, ethylene glycol butyl ether, ethylene glycol ethyl ether, ethylene glycol methyl ether, dioxane, cyclohexanone, amyl alcohol, sec-butyl alcohol, iso-butyl carbinol, diacetone alcohol
- the composition may be a synergistic composition.
- synergistic refers to a greater than additive effect that is produced by a combination of compounds selected from: (i) at least one essential oil; (ii) at least one metal species; and (iii) at least one cationic species, which exceeds the effect that would otherwise result from use of one or more of (i) to (iii).
- an article defined herein could be a substrate.
- the substrate could be an inert surface or it could comprise functional groups on at least one surface thereon, which can be used to anchor or immobilise a composition such as a coating.
- composition, film or coating may be immobilised on a variety of different substrates.
- suitable substrate materials include, but are not limited to: metals, ceramics, glass, polymers (such as plastics), materials of biological origin, woven and non-woven fibres, inert materials such as silicon, and combinations thereof.
- the substrate is selected from the group consisting of: plastics, metals, ceramics, woven materials, silicon materials, and combinations thereof
- composition, film or coating may utilise premade polymers that are covalently attached to the surface and cross-linked.
- Multifunctional cross-linkers allow both attachment to the surface and crosslinking between the components of polymer, which can provide the low fouling properties.
- Suitable metallic materials which may act as substrates include, but are not limited to: metals and alloys based on titanium, such as unalloyed titanium (ASTM F67) and titanium alloys, such as ASTM Fl 108, Ti-6A1-4V ELI (ASTM F136), Nitinol (ASTM F2063), nickel titanium alloys, and thermo-memory alloy materials; stainless steel (such as ASTM F138 and F139), tantalum (such as ASTM F560), palladium, zirconium, niobium, molybdenum, nickel-chrome, or certain cobalt alloys including Stellite, cobaltchromium (such as Vitallium, ASTM F75 and Wrought cobalt-chromium (ASTM F90)), and cobalt-chromium-nickel alloys (such as ELGILOY® and PHYNOX®).
- metals and alloys based on titanium such as unalloyed titanium (ASTM F67) and titanium alloys, such as ASTM Fl
- Suitable ceramics which may act as substrates include, but are not limited to: oxides, carbides, or nitrides of the transition elements such as titanium oxides, hafnium oxides, iridium oxides, chromium oxides, aluminium oxides, and zirconium oxides. Silicon based materials, such as silica, may also be used.
- Suitable polymer substrates include, but are not limited to: polystyrene and substituted polystyrenes, polyalkylenes, such as polyethylene and polypropylene, poly(urethane)s, polyacrylates and polymethacrylates, polyacrylamides and polymethacrylamides, polyesters (for example DACRON®), polysiloxanes, poly -ethers, poly(orthoesters), poly(carbonates), poly(hydroxyalkanoate)s, polyfluorocarbons (for example polytetrafluoroethylene), polyether ether ketone (PEEK), parylene based polymers, dopamine based polymers, hydrogen cyanide derived polymers (aminomalononitrile), silicones, epoxy resins, polyalkenes, phenolic resins, aromatic polyamides, natural and synthetic elastomers, adhesives and sealants, polyolefins, polysulfones, polyacrylonitrile, biopolymers such as polysacchari
- composition, film or coating may also be immobilised on to industrial or residential or other common substrates to prevent mildew, bacterial contamination, and in other applications where it is desirable to prevent fouling, such as: marine applications (ship hull coatings), fuel tanks, oil pipelines, industrial piping, pharmaceutical equipment, drug delivery devices such as inhalers, contact lenses, dental implants, coatings for in vivo sensors, textiles such as hospital drapes, gowns, or bedding, ventilation conduits, doorknobs, devices for separations, such as membranes for microbial suspension, biomolecule separation, protein fractionation, cell separation, waste water treatment, water purification, bioreactors, and food processing.
- marine applications ship hull coatings
- fuel tanks such as oil pipelines, industrial piping, pharmaceutical equipment
- drug delivery devices such as inhalers, contact lenses, dental implants, coatings for in vivo sensors
- textiles such as hospital drapes, gowns, or bedding
- ventilation conduits such as hospital drapes, gowns, or bedding
- doorknobs devices for separations, such as
- compositions or coatings may also be used to coat and thus treat surfaces of fibres, particulates and films for the applications of textiles, additives, electric/optical appliances, packaging materials and colorants/inks.
- the composition is formulated to form a film or coating.
- the composition may be applied in any form known in the art, on to at least a portion of a surface of an article.
- the composition may be formulated to be applied as a spray, as a paint, as a liquid, or incorporated into a device such a sleeve for a door handle, an adhesive cover, a protective covering, such as a film.
- the composition is formulated to provide an antipathogenic composition, film or coating.
- the composition is suitable for controlling, preventing and/or reducing the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
- the composition is an antibacterial, antifungal, and/or antiviral composition, film or coating.
- the composition is an antibacterial, antifungal, and/or antiviral composition, film or coating, and controls, reduces and/or eliminates at least one pathogen, and displays an efficacy for the at least one pathogen for about, or at least about: 1 day, 2 days, 3 days, 4 days, 5 days, 10 days, 15 days, 20 days, 25 days, 30 days, 35 days, 40 days, 45 days, 50 days, 55 days, or 60 days.
- the composition is an antibacterial composition, film or coating.
- the composition is an antibacterial composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a bacteria selected from, but not limited to: gram-negative bacteria, gram-positive bacteria, and mixtures thereof.
- the composition is an antibacterial composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a bacteria selected from: Pseudomonas aeruginosa, Staphylococcus aureus, and mixtures thereof.
- the composition is an antifungal composition, film or coating.
- the composition is suitable for controlling, preventing and/or reducing the concentration of a fungus, mildew, mould and mixtures thereof.
- the composition is an antiviral composition, film or coating.
- the composition is an antiviral composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a virus selected from: an enveloped virus, a non-enveloped virus, and mixtures thereof.
- the composition is an antiviral composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a virus selected from: SARS-CoV-2, or a surrogate of SARS-CoV-2, and mixtures thereof.
- composition is formulated as an antifouling composition, film or coating.
- the composition is formulated for an in vivo application, for example a coating for a medical device such as a catheter or an implant.
- the composition is antipathogenic, optionally in the form of a coating, wherein the efficacy of the composition provides a reduction in the concentration of at least one pathogen, in a time scale of less than about, or about: 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 90 minutes, 120 minutes, or 180 minutes.
- a reduction in the concentration of at least one pathogen may be a reduction of about, or at least about: 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.5%, or 99.9%, of the original concentration of the pathogen.
- the composition is an antipathogenic composition, optionally in the form of a film or coating (for example as shown in Figure 1), wherein the antibacterial, antifungal and/or antiviral efficacy of the composition provides a reduction in the concentration of at least one pathogen (for example a bacteria, virus and/or fungus), in a time scale of less than about, or about: 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 90 minutes, 120 minutes, or 180 minutes.
- pathogen for example a bacteria, virus and/or fungus
- a reduction in the concentration of a pathogen such as one or more bacteria, virus and/or fungus, may be a reduction of about, or at least about: 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.5%, or 99.9%, of the original concentration of the pathogen.
- composition described herein may be formulated to be applied to at least a portion of a surface of an article.
- the article may comprise or may be composed of a material selected from: wood, metal, plastic, and mixtures thereof.
- compositions described herein may comprise one or more film formers.
- a polymer base may comprise one or more film formers.
- a film former is a compound (or a mixture of compounds), that is capable of leaving a cohesive film or coating on a surface.
- the film or coating may be pliable.
- One or more film formers may comprise a cellulose and/or one or more polymers.
- polymers include, but are not limited to: acrylate copolymers, for example those obtained by emulsion polymerisation, for example, acrylate/Ci2-22 methacrylate copolymers polymerised from monomers of methacrylic acid, methyl methacrylate, butyl acrylate, and cetyl-eicosiyl methacrylate; and PPG-17/isophorone diisocyanate (IPDI)/dimethylol propionic acid (DMPA) copolymer; polyurethane polymer dispersions, for example Polyurethane-34 which is a sodium salt of polymerized monomers of adipic acid, 1,6-hexandiol, neopentyl glycol, hexamethylene diisocyanate, ethylene diamine, N-(2-aminoethyl)- 3 aminoethane sulphonic acid; Polyurethane -32 which is a sodium salt of polymerized monomers of polytetram
- composition may comprise one or more polyester copolymers, which may be fdm formers, such as those derived from diols, for example branched alkylene diols, for example, neopentyl glycol, and alkane diacids, such as adipic acid, alkane polyacids, or alkane or aryl acid anhydrides, such as trimellitic anhydride.
- polyester copolymers which may be fdm formers, such as those derived from diols, for example branched alkylene diols, for example, neopentyl glycol, and alkane diacids, such as adipic acid, alkane polyacids, or alkane or aryl acid anhydrides, such as trimellitic anhydride.
- the composition may form a film.
- the composition may be in the form of a coating.
- the components of the composition can be applied to an article for forming a film.
- a film or coating formed from a composition defined herein may be formed by a polymerisation reaction and/or drying.
- the composition may be formulated for use or application on a “high contact surface” or “high contact article”.
- the high contact surface” or “high contact article” may be a surface that is touched repeatedly by one individual or a plurality of different individuals, and more particularly a surface that is touched repeatedly in a short space of time, such as within 30 minutes, 10 minutes, 5 minutes or sub 1 minute intervals.
- Examples of such high contact surfaces include, but are not limited to door handles, petrol bowser handles, touchscreens or touchpads, particularly including those in public areas, such as payment terminals, ATMs, elevator buttons, light switches, kiosk / vending machine input buttons, or similar, keyboards, user input devices, such as a mouse, the like.
- this is not essential and the techniques described herein can be applied to a wide range of different contact surfaces and/or articles.
- composition may be formulated so that it can be applied to at least a portion of a surface, for example a high contact surface.
- the composition may be formulated so that it can be applied to at least a portion of a surface of an article selected from: a table, a door, a door handle, or a mixture thereof.
- the composition may be formulated to be applied to at least a portion of a surface of an article as a liquid composition, such as a paint or as a spray, or another form such as a paste, gel or an aerosol, which then dries to form a solid, for example a film.
- composition for example initially in the form of a liquid
- the composition is formulated to form a fdm or coating in a time in a range of about 1 minute to about 60 minutes, for example: about 1 minute to about 50 minutes, about 1 minute to about 40 minutes, about 1 minute to about 30 minutes, about 1 minute to about 20 minutes, about 1 minute to about 15 minutes, about 1 minute to about 10 minutes, or about 1 minute to about 5 minutes.
- Disclosed herein is a method of controlling, preventing and/or reducing the concentration of at least one pathogen, optionally selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof, the method comprising applying the composition as defined herein to at least a portion of a surface of an article.
- at least one pathogen optionally selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof
- compositions as defined herein to control, prevent and/or reduce the concentration of at least one pathogen, optionally selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
- compositions as defined herein in the formation of an antipathogenic film.
- compositions as defined herein as an antifouling composition, film or coating.
- compositions capable of forming an antipathogenic composition, film or coating comprising: at least one essential oil; at least one metal species; and at least one cationic species.
- composition of example embodiment 1 where the composition is in the form of a film or a coating.
- composition of example embodiment 1 or example embodiment 2 further comprising a polymer base, wherein the polymer base comprises one or more polymers and optionally one or more film formers. 4. The composition of example embodiment 3, wherein the one or more polymers are suitable for forming a film.
- composition of any one of example embodiments 2 to 4, wherein the polymer base comprises: a polymer comprising: a cellulose, a polyurethane, polyethylene terephthalate, an acrylate homopolymer or copolymer, and mixtures thereof.
- composition of example embodiment 5, wherein the cellulose is selected from one or more of: nitrocellulose, cellulose acetate, cellulose acetate butyrate, ethyl cellulose, and mixtures thereof.
- composition of any one of the preceding example embodiments, wherein the at least one metal species comprises at least one elemental metal.
- composition of any one of the preceding example embodiments, wherein the at least one metal species comprises at least one metal selected from: copper, silver, titanium aluminium, cobalt, gold, lead, magnesium, molybdenum, nickel, tin, zinc, zirconium, compounds thereof, salts thereof, oxides thereof, complexes thereof, mixtures thereof, and alloys thereof.
- composition of any one of example embodiments 1 to 10, wherein the at least one metal species is an oxide selected from: copper oxide, titanium oxide, and mixtures thereof.
- composition of any one of example embodiment 1 to 10, wherein the at least one metal species is an alloy. 16. The composition of any one of the preceding example embodiments, wherein the at least one metal species is a powder.
- composition of any one of the preceding example embodiments, wherein the at least one metal species is a particle with a mean diameter of about 50 nm to about 100 nm.
- organic solvent selected from: butyl acetate, ethyl acetate, ethyl alcohol, isopropanol, diacetone alcohol, acetone, and mixtures thereof.
- composition of example embodiment 29, wherein the organic solvent is selected from: alkylacetates, arylacetates, alcohols, ethers, ketones, alkanes, hydrocarbons, and mixtures thereof.
- composition of example embodiment 29 or example embodiment 30, wherein the organic solvent is selected from: butyl acetate, ethyl acetate, ethyl alcohol, isopropanol, diacetone alcohol, and mixtures thereof.
- compositions of example embodiment 39, wherein the aqueous solvent comprises sweat comprises sweat.
- composition of any one of the preceding example embodiments, wherein the composition is an antibacterial composition, film or coating.
- composition of any one of the preceding example embodiments, wherein the composition is an antifungal composition, film or coating
- composition of example embodiment 45 wherein the composition is suitable for controlling, preventing and/or reducing the concentration of a fungi, mildew, mould or a mixture thereof.
- compositions of any one of the preceding example embodiments, wherein the composition is an antibacterial composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a bacteria selected from: Gram-negative bacteria, Gram-positive bacteria, and mixtures thereof.
- compositions is an antibacterial composition, fdm or coating suitable for controlling, preventing and/or reducing the concentration of a bacteria selected from: Pseudomonas aeruginosa, Staphylococcus aureus, and mixtures thereof.
- composition of any one of the preceding example embodiments further comprising at least one other component, optionally selected from: iodine, graphene oxide, and mixtures thereof.
- composition of example embodiment 56, wherein the article comprises or is composed of a material selected from: wood, metal, plastic, and mixtures thereof.
- the liquid composition, solid composition or gaseous composition is formulated to dry in less than about: 5, 10, 15, 20, 25, or 30 minutes.
- a coating or fdm comprising the composition of any one of the preceding example embodiments.
- compositions of any one of example embodiments 1 to 62 to control, prevent and/or reduce the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
- a commercial nail polish formulation was used to incorporate compounds with anti-pathogen properties and to produce coatings.
- Poly E-L-lysine HC1 (MW 3,500- 5,000Da) and polyhexamethylene guanidine obtained from Biosynth Carbosynth®. Cinnamaldehyde, carvacrol, copper (II) oxide (nanopowder ⁇ 50nm particle size (TEM)), silver and copper nanoparticles were acquired from Sigma-Aldrich. Tea tree oil was purchased from Thursday Plantation.
- Silver-coated nanoparticles were obtained from Nanoshel containing copper 80% silver 20%, size 80-100 nm, purity 99.9%.
- Nutrient agar, Mueller-Hinton broth and sterile fdter paper were purchased form ThermoFisher Scientific (Oxoid). Aluminium discs were laser cut to various sizes and were used as substrates in the different assays.
- Gram-negative Pseudomonas aeruginosa ATCC 27853 and Gram-positive Staphylococcus aureus ATCC 25923 strains were employed. Bacterial stocks were prepared in 60% glycerol and stored at -80 °C until needed. All surfaces were sterilized with UV prior to the bacterial assay.
- X-ray photoelectron spectroscopy (XPS) analysis was used to characterize the surface chemistry (surface elemental composition) of the coatings.
- XPS analysis was performed using an AXIS Ultra-DUD spectrometer (Kratos Analytical Utd, U.K.) equipped with a monochromated Al-Ka X-ray source at a power of 180 W (12 mA, 15 kV).
- An internal electron flood gun was used to compensate for sample charging during irradiation. All elements presented were identified from low resolution survey spectra (acquired at a pass energy of 160 eV). The atomic concentrations of the detected elements were calculated using integral peak intensities and the sensitivity factors supplied by the manufacturer.
- Data processing was performed using CasaXPS processing software version 2.3.21(Casa Software Utd., Teignmouth, United Kingdom).
- Bacterial stocks were streaked onto nutrient agar plates to be used as working stock. After 24 hours incubation at 37 °C, a single colony from the streaked plate was used and inoculate in 10 mL of Mueller-Hinton broth (MHB) which was incubated overnight (180 rpm) at 37 °C. This culture was further diluted in MHB to obtain 10 6 colony-forming units per mL (cfu mL-1). Cultures were spread evenly onto agar plates using a sterile swab.
- MHB Mueller-Hinton broth
- Sterile fdter paper discs (6 mm 0 - Oxoid antimicrobial susceptibility test discs) previously coated with mixtures of the polymeric formulation and individual antimicrobial compounds at 5% concentration were gently pressed onto the surface of the agar plates.
- Discs coated with the polymeric fdm alone were used as controls. Plates were then inverted and incubated for approximately 24hours at 37 °C and the diameter of the inhibition zones was measured in mm, including the diameter of the disc.
- the bottom and walls of the wells in a 96 well plate were painted with a combination of two antimicrobial compounds and the polymeric formulation and dry overnight inside the biohazard cabinet.
- One hundred microlitres of the diluted bacterial suspensions (106 cfu mL -1 ) were pipetted into each well and incubate for 24 hours at 37 °C with gentle agitation (75 rpm). After overnight incubation, the cell suspensions were carefully removed, and the wells were rinsed twice with 110 pl of PBS per well to remove non-adherent cells.
- the plates were heat-fixed in a 60 °C oven for 1 hour and then stained with 100 pl of 1% (w/v) crystal violet for 10 minutes.
- the crystal violet was removed, and the plates were washed three times by immersing them in cold water to remove excess stain. Excess water after washing was removed by gently tapping the plates against paper towels. One hundred microliters of 95% ethanol were added to each well and the plate was incubated at room temperature for 10 minutes. One hundred microliters of solution from each well were transferred into a new plate. The biomass of biofilm from each well was determined by reading the optical density using a BioTek plate reader at 600 nm.
- bacterial stocks were streaked onto nutrient agar plates to be used as working stock. After 24 hours incubation at 37 °C, a single colony from the streaked plate was used and inoculate in 10 mL of MHB which was incubated overnight (180 rpm) at 37 °C.
- aluminium disks (6 mm 0 laser cut aluminium round discs) with both sides coated with the specific antipathogen combination were incubated for 24 hours at 37 °C with 50 pL of bacteria solution (106 cfu mL -1 ). After incubation samples were gently washed 3 times using sterile phosphate buffered saline (PBS) to remove any planktonic cell.
- PBS sterile phosphate buffered saline
- samples were individually transferred to a sterile Eppendorf tube containing ImL of sterile PBS. Samples were vortexed (3 times as 30 seconds) and sonicated for 10 minutes to detach bacterial biofdm from the surface. After sonication, samples were vortex again for 30 seconds. The suspensions obtained were serially diluted and aliquots of 20 pL were plated on nutrient agar plates for viable counts.
- the antibacterial activity observed from the metal nanoparticles in the zone of inhibition test could be attributed to the lack of diffusion of the nanoparticles from the fdter paper disc to the agar plate or the limited solubility of the ions and other species released by the nanoparticles into the agar plate.
- the diffusivity of nanoparticles with sizes greater than 10 nm in culture media is expected to be in the order of 10 -11 m 2 /s, which is lower compared to the diffusion of antibiotics commonly employed in this test.
- MRSA methicillin resistant Staph, aureus
- PHMB has been incorporated into for example polydimethylsiloxane (PDMS) films where inhibition of E. coli, Staph, aureus and Staph, epidermis among other strains has been reported at different loading concentrations (0.1, 0.3, 0.5% (w/w)).
- PDMS polydimethylsiloxane
- electrostatic adsorption as a result of its cationic nature has been the recognized mechanism of action.
- s-PL has been widely used in food applications but recently its uses have been expanded into the medical research and industrial areas.
- s-PL has been grafted to methacrylamide for the fabrication of hydrogels which showed a 3 -log reduction on the counts of P aureginosa in vitro.
- s-PL was cross-linked with catechol for the fabrication of antibacterial paint for medical devices.
- the coatings at the highest concentration of s-PL reported a 99.99% reduction in both Gram-positive and Gramnegative bacteria as well as the ability to inhibit biofilm formation for one week.
- 3 -log reduction in the viability was reported when concentrations greater than two times the minimum inhibitory concentrations were employed.
- s-PL was reported to hold the highest microbial selectivity over mammalian cells compared to other cationic polymers such as linear polyethylenimine (LPEI), cc-poly-D-lysine (PDL) and cc-poly-L-lysine (PLL), among others.
- LPEI linear polyethylenimine
- PDL cc-poly-D-lysine
- PLL cc-poly-L-lysine
- the surface of the three compounds combination was analysed by XPS. Coatings comprised of individual and two component combinations were prepared.
- the antimicrobial compositions were tested for the inactivation of human coronavirus OC43 (Infectivity Assay 1 - component antiviral testing) and to extend the testing of the antimicrobial composition on a panel of virus consisting of OC43, 229E and RVA1 (Infectivity Assay 2 - antiviral testing on a range of viruses). Infective Assay 1 - Antiviral Testing Using OC43
- 25 pL OC43 or control was applied to each material in sterile 24 well tissue culture plates. Test samples were incubated for one hour (class II BSC, lid of the plate left on).
- TCID virus infectivity assay media EMEM 1% FCS
- All samples were stored at -80 °C upon harvest, until infectivity assay.
- the remaining virus inoculum was stored at -80 °C.
- Figure 9 shows TCID values for OC43 infectious virus after exposure to the tested compounds.
- PB and PHMB component showed toxicity to MRC-5 cells. The toxicity of all other component was negligible.
- the viral infectivity of OC43 was significantly lower in the cinnamaldehyde and PHMB treated discs (p ⁇ 0.0005), in comparison to baseline.
- infectious virus was reduced for discs treated with Cu(II)O combined with cinnamaldehyde (p ⁇ 0.0005), but the reduction was comparable to cinnamaldehyde alone. Maximum reduction in infectious virus was observed for the double component cinnamaldehyde and lysine, as well as the LY and PB treated discs (p ⁇ 0.0005). For these three components, the reduction of infectious OC43 was greater than 99.9% in comparison to baseline (Table 3). In Table 3, the reduction was calculated based on averages using the following formula: 100* (baseline
- a negative value corresponds to a reduction of infectious virus in the tested compound, in comparison to baseline.
- Table 3 Percentage of reduction of OC43 infectious virus components after one hour exposure to tested components. Infectivity Assay 2- Antiviral Testing OC43, 229E and RVA1
- RVlB 4x 10 7 TCID50/mL (diluted in DMEM 1% FCS to give lx 10 6 TCID50/25 pL)
- virus were collected in 975 pL of TCID virus infectivity assay media (EMEM 1% FCS or 1% FCS DMEM ) and immediately transferred to a sterile 1.7mL tube. All samples were stored at -80 °C upon harvest, until infectivity assay.
- TCID virus infectivity assay media EMEM 1% FCS or 1% FCS DMEM
- the remaining virus inoculum were stored at -80 °C.
- Figure 10 shows TCID values for OC43 infectious virus after exposure to the tested compounds and Table 4 shows corresponding reduction percentage in comparison to baseline.
- a cell toxicity was observed for PB treated discs in RD-ICAM cells.
- the toxicity of the LY component was negligible.
- the viral infectivity assay showed a significant reduction in infectious RV-A1 both for the LY (*: p ⁇ 0.05; 60% reduction to baseline) and PB (**: p ⁇ 0.001; 63% reduction to baseline) treated discs in comparison to untreated discs.
- the reduction was calculated based on averages using the following formula: 100* (baseline - tested component)/baseline.
- a negative value corresponds to a reduction of infectious virus in the tested compound, in comparison to baseline.
- a positive value corresponds to an increase in infectious virus in the tested compounds, in comparison to baseline.
- Baseline at 1 hour post infection was compared to baseline infectious virus at 30 min of exposure.
- One technical replicate was excluded for the LY compound at 1 hour.
- Table 4 Percentage of reduction of RV-A1 infectious virus after exposure to LY or PB compounds for 30 minute or one hour
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Disclosed herein are compositions that may be formulated as coating compositions. The compositions comprise: (i) at least one essential oil; (ii) at least one metal species and/or (iii) at least one cationic species. The compositions may be used as antipathogenic compositions, antipathogenic films, or antipathogenic coatings. Also disclosed herein are methods for forming the compositions and possible uses and applications of said compositions including the potential formation of coatings on one or more articles.
Description
"COATING COMPOSITIONS"
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims priority from Australian Provisional Patent Application No. 2021904263, filed on 24 December 2021, the contents of which are incorporated herein by reference in their entirety.
TECHNICAL FIELD
The present disclosure relates to compositions which may be formulated as coating compositions. The compositions may be used as antipathogenic compositions, antipathogenic films, or antipathogenic coatings. The compositions disclosed herein may be applied across multiple industries including, but not limited to: infrastructure, construction, food processing/packaging, manufacturing and/or medical applications.
BACKGROUND
COVID-19 has irreversibly changed the way we live highlighting the risk of disease and societal impacts caused by respiratory viruses such as SARS-CoV-2. Furthermore, with the growth of antimicrobial resistance, society needs innovative solutions to ensure that people can continue to live safe and healthy lives. In the absence of drugs or vaccines, it is human behaviour that becomes the primary weapon to control the spread of disease. Prevention of infection through inactivation of pathogens on surfaces is crucial to ongoing control of disease transmission. It will also play an important role in the restoration of business confidence and reducing the risk to public health due to surface contamination.
The global pandemic associated with the coronavirus SARS-CoV-2 and the looming threat of a global health crisis associated with antimicrobial resistance have both highlighted the need for anti -pathogenic technologies. Despite the availability of agents with both antimicrobial and antiviral properties, simultaneous reduction of the infectivity of both microorganisms is limited by their different mechanisms of action.
The ability of pathogens, such as the SARS-CoV-2 virus, to remain on surfaces such as stainless steel and plastic for hours, as well as the ability of bacterial biofilms to display inherent resistance against antimicrobial agents have created immense challenges for the healthcare system and the demand for anti-infective surfaces. The U.S. Centers for Disease Control and Prevention notes that people can be infected with SARS-CoV-2
through contact with surfaces. CSIRO’s Australian Centre for Disease Preparedness (ACDP)’s research on SARS-CoV-2 survivability found that the virus can survive for up to 28 days on common surfaces including banknotes, glass (such as mobile phone screens), and stainless steel. Additionally, surface transmission in hotel quarantine has already been attributed by health authorities to have sparked a cluster in Adelaide’s northern suburbs which led to South Australia’s lockdown in November 2020.
Routine sanitisation and disinfection of surfaces to reduce the spread of pathogens, for example hospital-related bacteria have been implemented. However, increased use of common disinfectants products containing quaternary ammonium compounds, hydrogen peroxide, bleach and alcohols may cause detrimental effects on human health and the environment. The repeated application of disinfectant processes may be labour intensive, with efficacy waning over a limited period, such as over minutes as opposed to hours. Moreover, the costs associated with routine cleaning of the surfaces are high and may not guarantee their complete decontamination. Anti-infective surfaces where antipathogenic agents (such as antiviral/antibacterial agents) are released over time would reduce the cost of routine sanitisation by decreasing the survival of pathogens for longer periods.
SARS-CoV-2 is one of many pathogens causing problems around the globe. The synthesis and application of materials and coatings that could assist in reducing or eliminating the presence of one or more pathogens could potentially reduce the number of people being affected by infections, and potentially prevent serious illnesses.
Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each of the appended claims.
SUMMARY
Disclosed herein is a composition capable of forming an antipathogenic film or coating, the composition comprising: (i) at least one essential oil; (ii) at least one metal species; and (iii) at least one cationic species.
Disclosed herein is a method of controlling, preventing and/or reducing the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof, the method comprising applying a composition as defined herein, to at least a portion of a surface of an article.
Disclosed herein is the use of a composition as defined herein, to control, prevent and/or reduce the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
Disclosed herein is the use of a composition as defined herein in the formation of an antipathogenic composition, film or coating.
Disclosed herein is the use of a composition as defined herein as an antifouling composition, film or coating.
Disclosed herein is a composition comprising a combination of compounds selected from: (i) at least one essential oil; (ii) at least one metal species; and (iii) at least one cationic species. The composition may also use a polymer to provide increased antipathogenic activity (for example antibacterial, antiviral and/or antifungal activity,) potentially via a synergistic combination of combined compounds, based on the pathogen or groups of pathogens that need to be controlled or eliminated.
Herein “pathogen” refers to a microorganism that can potentially cause a disease or illness in an organism, and includes: a virus, bacterium, protozoan, prion, viroid, or fungus.
"Antipathogenic" or “antipathogen” as used herein, refers to molecules and/or compositions that kill and/or prevent fouling by microorganisms including: bacteria, yeast, fungi, mycoplasma, and viruses.
Herein the term "antipathogenic activity" is defined as an activity that kills or inhibits the growth of microorganisms including, but not limited to bacteria, viruses, parasites, and fungi.
It will be understood that a reference to the term “antipathogenic”, “antipathogenic agent”, “antipathogenic compound” and the like herein encompasses, the antipathogenic/antipathogenic agent/antipathogenic compound and, where permitted, all derivatives, isomeric forms, racemates, amorphous forms, crystalline forms, solvates, acceptable salts, solvates of said salts, and prodrugs thereof in isolation from one another as well as mixtures.
Herein the composition may comprise a polymer base. The polymer base may provide a medium that allows the composition to adhere to at least a portion of an article, comprising or composed of a material, such as wood, metal and/or plastics. The polymer base may also act as a vehicle for the components of the composition (for example (i) at least one essential oil; (ii) at least one metal species; and (iii) at least one cationic species), to move through the article (for example a substrate) and onto one or more surfaces. The polymer base may comprise one or more film formers.
In one embodiment, the components of a composition described herein are activated to control, reduce and/or eliminate the concentration of at least one pathogen, once the polymer base is in contact with an aqueous solution or solvent. The aqueous solution may, for example, be the sweat of a person contacting the composition, such as from the hand of a subject contacting the composition disposed on an article, such as a door handle. The composition may therefore have a “start stop” mechanism, wherein the composition controls, reduces and/or eliminates one or more pathogens whilst an appropriate concentration of water and/or an appropriate solvent is provided. This mode of action may preserve the longevity of the composition, and in one embodiment, extend the antipathogenic activity of the composition. This mechanism may also minimise the overuse of antipathogenic compounds, when not necessary, reducing the chance of developing any associated resistance to one or more pathogens, and/or its overall environmental impact. In one example, the antipathogenic compounds contained in a composition disposed on an article become mobile and active when wiped down by a wet cloth during normal sanitation process.
The compositions may also be able to be tailored for specific applications and/or the materials that the compositions are to be applied. For example, the type and concentration of the components. The thickness of any composition, for example a composition comprising a polymer base may be controlled, for example by applying multiple layers of the same composition after an earlier applied composition has been applied. This may be appropriate in manufacturing settings, wherein equipment can be coated with the antipathogenic composition, film or coating, to create a protective barrier when in contact with disease causing materials.
The composition may be tailored using different polymer bases. These polymer bases can be in the form of commercially available products. For example, a paint formulation used in an air conditioning unit, may comprise the antipathogenic formulation (being i) at least one essential oil, ii) at least one metal species, and iii) at least one cationic species), thereby creating a purified surface or air flow.
The composition may also be tailored so numerous application techniques are viable, the composition could be applied as a liquid, a paste or aerosol. For example, the composition may be sprayed onto a surface through a manual mechanism such as a spray bottle activated by a hand trigger. In large-scale manufacturing settings, it may also be spray coated by a high-pressure nozzle onto products before they are sent to market. Large scale mixing processes of the composition into the bulk of a material may also be used for high volume manufacturing. In addition, the components of the composition can
be tailored to target specific pathogens or groups of pathogens. For example, the composition may be tailored with a group of compounds displaying the highest efficacy for one or more pathogens. During a pandemic, or outbreak, the composition may be adapted to provide efficacy for the pandemic pathogen, and potentially adapted again to account for variants of said pathogens.
The composition may be tailored so that it can be removed with a solvent, optionally removed to re-apply a fresh amount of the composition after an appropriate period of use/application has elapsed. This may be useful in construction mould remediation settings, where continued application of the composition may create layers too thick for purpose. The removability of this layer allows a fresh coat to be added without a build-up of previous coatings.
The compositions described herein may be used to potentially reduce the risk for acquiring infectious diseases through surface transmission, for example in environments where care is provided to vulnerable residents such as aged care facilities or hospitals, as well as in high-density environments. A single application of a composition described herein may control, reduce and/or eliminate one or more bacteria, viruses and/or fungi.
The composition may be used on medical devices to be implanted inside the human body. Wherein the antipathogenic composition, film or coating, has a biocompatible nature, it may be used on medical devices like catheters that are inserted into the body, which require a high level of antipathogenic activity over long periods of time.
The compositions described herein may display efficacy for an extended period, for example the compositions may display an efficacy against one or more pathogens or microbes for 30 or more days. The compositions may display an efficacy of 30 or more days during continuous use during this period, for example without the need for a further application of the same or different composition. An instance of this is that it may be used in the food industry for packaging of agricultural food products to be shipped to consumers. For example, an anti-pathogenic layer on food packaging that continuously kills for multiple days may allow it to reduce mould growth and extend the shelf-life of food.
The compositions described herein may provide advantages such as saving on costs for a business or an organisation by assisting in the simplification of sanitation processes, for example by relieving staff of the need to disinfect as often. This may save on the amount of hours and material needed to disinfect commonly touched surfaces and the costs associated with this time and effort. The composition may prophylactically kill
pathogens, reducing the need for other surfaces to be as frequently disinfected via other means. For example, from the application of a chemical or the use of wipes. This may save on the amount of hours and material needed to disinfect commonly touched surfaces, reducing excess waste and improving its environmental friendliness, for example in high-density environments.
The compositions may provide higher public safety outcomes. By reducing the amount of hours for disinfection, this may reduce the risk for parties such cleaners acquiring infectious diseases from areas such as high-density environments. The compositions herein may therefore provide a means to improve safety, whilst also potentially saving on labour intensive cleaning processes.
The compositions described herein may provide one or more of the following advantages:
• an acceptable, high or sufficiently high pathogen kill rate
• a broad spectrum with regards to the variety of pathogens killed or the reduction in number of said pathogens
• the safety of the composition and its ingredients in regards to its application and/or use on an article or surface thereof
• longevity in relation to antimicrobial activity and/or general physical stability, especially when applied to high contact articles or high contact surfaces
• the ability to tailor the compositions for application to a specific surface or article, or required application
• the speed at which the composition can be applied and/or to dry and/or
• an advantageous price per unit or application.
It will be appreciated that the embodiments of each aspect of the present disclosure may equally be applied to each other aspect, mutatis mutandis.
BRIEF DESCRIPTION OF DRAWINGS
Whilst it will be appreciated that a variety of embodiments disclosed herein may be utilised, in the following, described herein are a number of examples with reference to the following drawings:
Figure 1 - Schematic of the antipathogen coating containing the three- components including an essential oil, a metal compound and a cationic polymer.
Figure 2 - Activity of different compounds evaluated using the zone of inhibition test against Staph, aureus. The compounds tested were: A) polymeric formulation (control); B) AgCu nanoparticles; C) copper oxide (Cu(II)O); D) cinnamaldehyde; E) carvacrol; F) tea tree oil; G) s-poly-L-lysinc (a-PL); and H) PHMB.
Figure 3 - Antibacterial activity of different compounds evaluated using the zone of inhibition test against P. aeruginosa. The compounds tested were: A) polymeric formulation (control); B) AgCu nanoparticles; C) copper oxide (Cu(II)O); D) cinnamaldehyde; E) carvacrol; F) tea tree oil; G) a-PL; and H) PHMB.
Figure 4 - Graph of crystal violet test of biofdm mass vs combination of two antipathogenic compounds against Staph, aureus.
Figure 5 - Graph of crystal violet test of biofdm mass vs combination of two antipathogenic compounds against P. aeruginosa.
Figure 6 - Graph of biofdm experiment using aluminium substrates. Logarithmic reduction of the cfu/mL obtained from the viable counting of the samples. Both Staph, aureus and P. aeruginosa were evaluated.
Figure 7 - Pictures of 96 well plate biofdm experiment using three components combination. Agar plates labelled with number one used Staph, aureus while number two represent P. aeruginosa. Combination 1: A 1-2) control samples - polymeric fdm; Bl-2) Ag-Cu/Cinnamaldchydc/s-PL. Combination 2: Cl-2) Ag- Cu/Cinnamaldehyde/PHMB; DI -2) Cu(II)O/Cinnamaldehyde/8-PL; El -2) Cu(II)O/Cinnamaldehyde/PHMB .
Figure 8 - Graph of Log (cfu/mL) vs A) Control samples - polymeric fdm. B) Ag-Cii/cinnamaldchydc/s-PL. C) Ag-Cu/cinnamaldehyde/PHMB. D) Cu(II)O/cinnamaldehyde/ s-PL. E) Cu(II)O/cinnamaldehyde/PHMB, for Staph, aureus and P. aeruginosa.
Figure 9 - Graph of antiviral infectivity assay for a group of antipathogenic components vs OC43.
Figure 10 - Graphs of antiviral infectivity assay for a group of antipathogenic components vs RV-A1 on A - a logarithmic scale; and B - a linear scale.
DESCRIPTION OF EMBODIMENTS
Terms and Definitions
With regards to the definitions provided herein, unless stated otherwise, or implicit from context, the defined terms and phrases include the provided meanings. Unless explicitly stated otherwise, or apparent from context, the terms and phrases below do not exclude the meaning that the term or phrase has acquired by a person skilled in the relevant art. The definitions are provided to aid in describing particular embodiments, and are not intended to limit the claimed invention, because the scope of the invention is limited only by the claims. Furthermore, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
All publications discussed and/or referenced herein are incorporated herein in their entirety, unless described otherwise.
Unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular. Throughout this disclosure, unless specifically stated otherwise or the context requires otherwise, reference to a single step, composition of matter, group of steps or group of compositions of matter shall be taken to encompass one and a plurality (i.e., one or more) of those steps, compositions of matter, groups of steps or groups of compositions of matter. Thus, as used herein, the singular forms “a”, “an” and “the” include plural aspects unless the context clearly dictates otherwise. For example, reference to “a” includes a single as well as two or more; reference to “an” includes a single as well as two or more; reference to “the” includes a single as well as two or more and so forth.
Those skilled in the art will appreciate that the disclosure herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the disclosure includes all such variations and modifications. The disclosure also includes all of the examples, steps, features, methods, compositions, formulations, and processes, referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features.
The term “and/or”, e.g., “X and/or Y” shall be understood to mean either “X and Y” or “X or Y” and shall be taken to provide explicit support for both meanings or for either meaning.
Unless otherwise indicated, the terms “first,” “second,” etc. are used herein merely as labels, and are not intended to impose ordinal, positional, or hierarchical requirements on the items to which these terms refer. Moreover, reference to a “second”
item does not require or preclude the existence of lower-numbered item (e.g., a “first” item) and/or a higher-numbered item (e.g., a “third” item).
As used herein, the phrase “at least one of’ or “one or more of’ when used with a list of items, means different combinations of one or more of the listed items may be used and only one of the items in the list may be needed. The item may be a particular object, thing, or category. In other words, “at least one of’ means any combination of items or number of items may be used from the list, but not all of the items in the list may be required. For example, “at least one of item A, item B, and item C” may mean item A; item A and item B; item B; item A, item B, and item C; or item B and item C. In some cases, “at least one of item A, item B, and item C” may mean, for example and without limitation, two of item A, one of item B, and ten of item C; four of item B and seven of item C; or some other suitable combination.
It is to be appreciated that certain features that are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any sub-combination.
Throughout the present specification, various aspects and components of the disclosure can be presented in a range format. The range format is included for convenience and should not be interpreted as an inflexible limitation on the scope of the present disclosure. Accordingly, the description of a range should be considered to have specifically disclosed all the possible sub-ranges as well as individual numerical values within that range, unless specifically indicated. For example, description of a range such as from 1 to 5 should be considered to have specifically disclosed sub-ranges such as from 1 to 3, from 1 to 4, from 1 to 5, from 2 to 4, from 2 to 5, from 3 to 5 etc., as well as individual and partial numbers within the recited range, for example, 1, 2, 3, 4, 4.5, and 5, unless where integers are required or implicit from context. This applies regardless of the breadth of the disclosed range. Where specific values are required, these will be indicated in the specification.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
Throughout this specification, the term "consisting essentially of is intended to exclude elements which would materially affect the properties of the claimed composition, although may include elements that do not materially affect properties.
The terms "comprising", "comprise" and "comprises" herein are intended to be optionally substitutable with the terms "consisting essentially of, "consist essentially of, "consists essentially of, "consisting of, "consist of and "consists of, respectively, in every instance.
“Article”, as used herein, refers to an object or substrate, comprising one or more materials, on which a composition as described herein, optionally in the form of a coating, is applied, or is incorporate on or within, or on which the composition is immobilised.
Herein "coating", refers to any temporary, semi-permanent or permanent layer, or layers, treating or covering a surface, or a portion thereof of an article. The coating may be a chemical modification of at least a portion of the underlying article or may involve the addition of new materials to at least a portion of an article. It includes any increase in thickness to the substrate or change in surface chemical composition of at least a portion of the article. A coating may be applied as a liquid, for example as a paint or spray, and solidified into a solid coating. The coating may be applied as and/or comprise a single layer of a composition (and may take the form of a film), or the coating may be applied as and/or comprise a plurality of layers of one or more compositions. The plurality of layers may be the same or comprise different compositions. In one embodiment the coating comprises a single composition. The coating may be contiguous over a surface of an article, or may be present on at least a portion of a surface of an article.
Herein “film” refers to a material, including a coating, deposited or used in thin sections or layer form. The layer may be contiguous over a surface of an article, or may be present on at least a portion of a surface of an article.
Herein the % may relate to v/v, w/w or w/v, unless specifically described.
Herein, unless indicated otherwise, the term “about” encompasses a 10% tolerance in any value or values connected to the term.
Herein an “essential oil” may comprise any one or more oils, said oils which may be water insoluble, or substantially water-insoluble. One or more essential oils may be soluble in one or more of: an alcohol, an ether, an organic solvent, such as a hydrocarbon, and mixtures thereof. In one embodiment the solubility of one or more essential oil may be less than about 5, 4, 3, 2 1, or 0.5 % by weight in water at 25 °C or, optionally, less than about 0.1%.
Herein, the one or more essential oils may be volatile aromatic oils which may be synthetic or may be derived from plants by distillation, expression or extraction, and may carry the odour or flavour of the plant from which they are obtained. One or more
essential oils may provide antiseptic activity. Examples of essential oils include but are not limited to: citra, thymol, menthol, methyl salicylate (wintergreen oil), eucalyptol, carvacrol, camphor, anethole, carvone, eugenol, isoeugenol, limonene, osimen, n-decyl alcohol, citronel, a-salpineol, methyl acetate, cloves, citronellyl acetate, methyl eugenol, cineol, linalool, ethyl linalaol, safrole, vanillin, spearmint oil, peppermint oil, lemon oil, orange oil, sage oil, rosemary oil, cinnamon oil, pimento oil, laurel oil, cedar leaf oil, gerianol, verbenone, anise oil, bay oil, benzaldehyde, bergamot oil, bitter almond, chlorothymol, cinnamic aldehyde, citronella oil, eucalyptus oil, guaiacol, tropolone derivatives such as hinokitiol, lavender oil, mustard oil, phenol, phenyl salicylate, pine oil, pine needle oil, sassafras oil, spike lavender oil, storax, thyme oil, tolu balsam, terpentine oil, and mixtures thereof.
In certain embodiments, the essential oils are selected from the group consisting of thymol ((CHs CHCeHs CH OH, also known as isopropyl-m-cresol), eucalyptol (CioHisO, also known as cineol), menthol (CHsCeH^Cs^OH), also known as hexahydrothymol), methyl salicylate (CeEEOHCOOCHs, also known as wintergreen oil), isomers of each of these compounds, and combinations of two or more thereof.
The present disclosure considers salts of essential oils or components of essential oils such as the salts of monoterpenoid compounds. An example of a monoterpenoid compound is thymol. Thus, the present disclosure contemplates salts of thymol as acceptable salts. For example, an acceptable salt of thymol is the berberine ammonium cation salt of thymol and, vice versa, an acceptable salt of berberine is the thymol phenolate salt of berberine. It will be recognised that such a salt may display a combination of the biological activity possessed by the berberine ammonium cation and the biological activity possessed by the thymol phenolate counter anion.
Compositions
Disclosed herein is a composition which may be used for forming an antipathogenic composition, fdm or coating, the composition comprising:
(i) at least one essential oil
(ii) at least one metal species and
(iii) at least one cationic species.
Herein the composition comprises at least one essential oil. In one embodiment the at least one essential oil may be or an extract of: cloves, thyme, fennel, caraway, peppermint, lemon myrtle, tea tree, thymol, carvacrol, eugenol, menthol, terpineol, carvone, citral, arborvitae, Asteraceae, Bergamot, cajuput, Cassia, Cedarwood,
Cinnamon, Citron, clary sage, coriander, Eucalyptis, fennel, frankincense, lavender, lemon, lemongrass, Manuka, oregano, Perilla, rosemary, white fir, wild orange, wintergreen, ylang, or mixtures thereof.
In one embodiment the at least one essential oil may be selected from: cinnamaldehyde, tea tree oil, carvacrol, or mixtures thereof.
In one embodiment, one or more essential oils may be present in a range of about 0.05% v/v to about 10% v/v, or about 0.1 % v/v to about 5% v/v , or about 0.5 % v/v to about 3% v/v ; or in a range of about 0.05% w/v to about 10% w/v, or about 0.1 % w/v to about 5% w/v, or about 0.5% w/v to about 3% w/v; or in a range of about 0.05% w/w to about 10% w/w, or about 0.1% w/w to about 5% w/w, or about 0.5% w/w to about 3% w/w.
In one embodiment, one or more essential oils may be present in an amount of about, or at least about: 0.05% v/v, 0.1%, v/v, 0.5% v/v, 1% v/v, 1.5% v/v, 2% v/v, 2.5% v/v, 3% v/v, 3.5% v/v, 4% v/v, 4.5% v/v, 5% v/v, 5.5% v/v, 6% v/v, 6.5% v/v, 7% v/v, 7.5% v/v, 8% v/v, 8.5% v/v, 9% v/v, 9.5% v/v, or 10% v/v. In another embodiment, one or more essential oils may be present in an amount of about, or at least about: 0.05% w/v, 0.1%, w/v, 0.5% w/v, 1% w/v, 1.5% w/v, 2% w/v, 2.5% w/v, 3% w/v, 3.5% w/v, 4% w/v, 4.5% w/v, 5% w/v, 5.5% w/v, 6% w/v, 6.5% w/v, 7% w/v, 7.5% w/v, 8% w/v, 8.5% w/v, 9% w/v, 9.5% w/v, or 10% w/v. In another embodiment, one or more essential oils may be present in an amount of about, or at least about: 0.05% w/w, 0.1%, w/w, 0.5% w/w, 1% w/w, 1.5% w/w, 2% w/w, 2.5% w/w, 3% w/w, 3.5% w/w, 4% w/w, 4.5% w/w, 5% w/w, 5.5% w/w, 6% w/w, 6.5% w/w, 7% w/w, 7.5% w/w, 8% w/w, 8.5% w/w, 9% w/w, 9.5% w/w, or 10% w/w.
Herein the composition comprises at least one metal species. In one embodiment, the at least one metal species comprises at least one elemental metal.
In another embodiment, at least one metal species, or all the metal species, may be replaced with at least one transition element, for example selenium, or a salt, oxide or complex thereof.
Herein the metal species may be or comprise one or metals (for example as a mixture or elements and/or compounds, or alloys). In one embodiment, the at least one metal species comprises at least one metal selected from: copper, silver, titanium aluminium, cobalt, gold, lead, magnesium, molybdenum, nickel, tin, zinc, zirconium, compounds thereof, mixtures thereof, and alloys thereof.
In one embodiment, at least one metal species is an oxide. Examples of oxides include, but are not limited to: copper oxide, titanium oxide, aluminium oxide, cobalt oxide, magnesium oxide, nickel oxide, tin oxide, zinc oxide and mixtures thereof.
In one embodiment the at least one metal species is a salt.
In one embodiment the at least one metal species is a complex.
In one embodiment, at least one metal species is a mixture of metals.
In one embodiment, at least one metal species is an alloy.
The at least one metal species may be used in any form known in the art. In one embodiment, the at least one metal species may be in the form of a powder. In another embodiment the at least one metal species may be in the form of a particle. In yet another embodiment the at least one metal species may be colloidal. The at least one metal species may be in the form of a coated particle, for example a metal particle comprising a mixture of metals, for example silver and copper.
The at least one metal species may comprise particles on the nanoscale. For example, the at least one metal species may be a particle with a mean diameter of about, or at least about: 50 nm to about 100 nm. The at least one metal species may have a mean diameter of about, or at least about: 1 nm, 5 nm, 10, nm, 15 nm, 20 nm, 25 nm, 30 nm, 35 nm, 40 nm, 45 nm, 50 nm; 55 nm; 60 nm; 65 nm; 70 nm; 75 nm; 80 nm; 85 nm; 90 nm; 95 nm; or 100 nm.
In one embodiment, one or more metal species may be present in a range of about 0.05% v/v to about 10% v/v, or about 0.1 % v/v to about 5% v/v , or about 0.5 % v/v to about 3% v/v ; or in a range of about 0.05% w/v to about 10% w/v, or about 0.1 % w/v to about 5% w/v, or about 0.5% w/v to about 3% w/v; or in a range of about 0.05% w/w to about 10% w/w, or about 0.1% w/w to about 5% w/w, or about 0.5% w/w to about 3% w/w.
In one embodiment, one or more metal species may be present in an amount of about, or at least about: 0.05% v/v, 0.1%, v/v, 0.5% v/v, 1% v/v, 1.5% v/v, 2% v/v, 2.5% v/v, 3% v/v, 3.5% v/v, 4% v/v, 4.5% v/v, 5% v/v, 5.5% v/v, 6% v/v, 6.5% v/v, 7% v/v, 7.5% v/v, 8% v/v, 8.5% v/v, 9% v/v, 9.5% v/v, or 10% v/v. In another embodiment, one or more metal species may be present in an amount of about, or at least about: 0.05% w/v, 0.1%, w/v, 0.5% w/v, 1% w/v, 1.5% w/v, 2% w/v, 2.5% w/v, 3% w/v, 3.5% w/v, 4% w/v, 4.5% w/v, 5% w/v, 5.5% w/v, 6% w/v, 6.5% w/v, 7% w/v, 7.5% w/v, 8% w/v, 8.5% w/v, 9% w/v, 9.5% w/v, or 10% w/v. In another embodiment, one or more metal species may be present in an amount of about, or at least about: 0.05% w/w, 0.1%, w/w, 0.5% w/w, l% w/w, 1.5% w/w, 2% w/w, 2.5% w/w, 3% w/w, 3.5% w/w, 4% w/w, 4.5%
w/w, 5% w/w, 5.5% w/w, 6% w/w, 6.5% w/w, 7% w/w, 7.5% w/w, 8% w/w, 8.5% w/w, 9% w/w, 9.5% w/w, or 10% w/w.
Herein the composition comprises at least one cationic species.
Examples of cationic species include, but are not limited to:
(i) quaternary ammonium compounds, such as those in which one or two of the substituents on the quaternary nitrogen has from 8 to 20, for example from 10 to 18 carbon atoms, such as an alkyl group, which may optionally be interrupted by an amide, ester, oxygen, sulfur, or heterocyclic ring, while the remaining substituents have a lower number of carbon atoms, for instance from 1 to 7, and are optionally alkyl, for instance methyl or ethyl, or benzyl. Examples of such compounds include benzalkonium chloride, dodecyl trimethyl ammonium chloride, benzyl dimethyl stearyl ammonium chloride, hexadecyltrimethyl ammonium bromide, benzethonium chloride (diisobutyl phenoxyethoxyethyl dimethyl benzyl ammonium chloride) and methyl benzethonium chloride;
(ii) pyridinium and isoquinolinium compounds, including hexadecylpyridinium chloride and alkyl isoquinolinium bromides;
(iii) pyrimidine derivatives such as hexetidine (5-amino-l,3-bis(2-ethylhexyl)- 5 -methyl -hexahydropyrimidine) ;
(iv) amidine derivatives such as hexamidine isethionate (4,4'-diamidino-a,co- diphenoxy-hexane isethionate);
(v) bispyridine derivatives such as octenidine dihydrochioride (N,N'[l,10- decanediyldi-1 (4H)-pyridinyl-4-ylidene]-bis (1-octanamine) dihydrochioride);
(vi) guanides, for example, mono-biguanides such as p- chlorobenzylbiguanide and N'(4-chlorobenzyl)-N" -(2,4-dichlorobenzyl) biguanide, poly(biguanides) such as polyhexamethylene biguanide hydrochloride; and/or
(vii) N"-acyl amino acid alkyl esters and salts; and
(viii) mixtures thereof.
In one embodiment, one or more cationic species may be present in a range of about 0.05% v/v to about 10% v/v, or about 0.1 % v/v to about 5% v/v , or about 0.5 % v/v to about 3% v/v ; or in a range of about 0.05% w/v to about 10% w/v, or about 0.1 % w/v to about 5% w/v, or about 0.5% w/v to about 3% w/v; or in a range of about 0.05%
w/w to about 10% w/w, or about 0.1% w/w to about 5% w/w, or about 0.5% w/w to about 3% w/w.
In one embodiment, one or cationic species may be present in an amount of about, less than about, or at least about: 0.05% v/v, 0.1%, v/v, 0.5% v/v, 1% v/v, 1.5% v/v, 2% v/v, 2.5% v/v, 3% v/v, 3.5% v/v, 4% v/v, 4.5% v/v, 5% v/v, 5.5% v/v, 6% v/v, 6.5% v/v, 7% v/v, 7.5% v/v, 8% v/v, 8.5% v/v, 9% v/v, 9.5% v/v, or 10% v/v. In another embodiment, one or more cationic species may be present in an amount of about, less than about, or at least about: 0.05% w/v, 0.1%, w/v, 0.5% w/v, 1% w/v, 1.5% w/v, 2% w/v, 2.5% w/v, 3% w/v, 3.5% w/v, 4% w/v, 4.5% w/v, 5% w/v, 5.5% w/v, 6% w/v, 6.5% w/v, 7% w/v, 7.5% w/v, 8% w/v, 8.5% w/v, 9% w/v, 9.5% w/v, or 10% w/v. In yet another embodiment, one or more cationic species may be present in an amount of about, less than about, or at least about: 0.05% w/w, 0. 1%, w/w, 0.5% w/w, 1% w/w, 1.5% w/w, 2% w/w, 2.5% w/w, 3% w/w, 3.5% w/w, 4% w/w, 4.5% w/w, 5% w/w, 5.5% w/w, 6% w/w, 6.5% w/w, 7% w/w, 7.5% w/w, 8% w/w, 8.5% w/w, 9% w/w, 9.5% w/w, or 10% w/w.
In one embodiment the cationic species is a cationic polymer. The cationic polymer may be a homopolymer or a copolymer. In one embodiment the cationic polymer is a homopolymer. In another embodiment the cationic polymer is a copolymer, for example a statistical, gradient or block copolymer.
The cationic polymer may comprise one or more monomers selected from: lysine, hexamethylene guanidine, imidazolium, piperidinium, quaternary ammonium, ethylenimine, 2-dimethy(aminoethyl) methacrylate, chitosan, and mixtures thereof.
In one embodiment a polymer of lysine is used. Examples of lysine polymers include polymers of L-lysine and D-lysine. The lysine polymers may be in the a or s form. The lysine polymer may be: a-poly(L-lysine), a-poly(D-lysine), 8-poly (L-lysine), e-poly(D-lysine), or a mixture thereof. In one embodiment the cationic polymer is 8- poly (L-lysine).
The cationic polymer may be a salt known in the art. For example, the cationic polymer may be a salt selected from: a halo salt such as a chloride salt, a sulfate salt, a nitrate salt, or a mixture thereof.
In one embodiment, one or more cation polymers may be present in a range of about 0.05% v/v to about 10% v/v, or about 0.1 % v/v to about 5% v/v , or about 0.5 % v/v to about 3% v/v ; or in a range of about 0.05% w/v to about 10% w/v, or about 0.1 % w/v to about 5% w/v, or about 0.5% w/v to about 3% w/v; or in a range of about 0.05%
w/w to about 10% w/w, or about 0.1% w/w to about 5% w/w, or about 0.5% w/w to about 3% w/w.
In one embodiment, one or cationic polymers may be present in an amount of about, less than about, or at least about: 0.5% v/v, 1% v/v, 1.5% v/v, 2% v/v, 2.5% v/v, 3% v/v, 3.5% v/v, 4% v/v, 4.5% v/v, 5% v/v, 5.5% v/v, 6% v/v, 6.5% v/v, 7% v/v, 7.5% v/v, 8% v/v, 8.5% v/v, 9% v/v, 9.5% v/v, or 10% v/v. In another embodiment, one or more cationic polymers may be present in an amount of about, less than about, or at least about: 0.5% w/v, 1% w/v, 1.5% w/v, 2% w/v, 2.5% w/v, 3% w/v, 3.5% w/v, 4% w/v, 4.5% w/v, 5% w/v, 5.5% w/v, 6% w/v, 6.5% w/v, 7% w/v, 7.5% w/v, 8% w/v, 8.5% w/v, 9% w/v, 9.5% w/v, or 10% w/v. In yet another embodiment, one or more cationic polymers may be present in an amount of about, less than about, or at least about: 0.5% w/w, l% w/w, 1.5% w/w, 2% w/w, 2.5% w/w, 3% w/w, 3.5% w/w, 4% w/w, 4.5% w/w, 5% w/w, 5.5% w/w, 6% w/w, 6.5% w/w, 7% w/w, 7.5% w/w, 8% w/w, 8.5% w/w, 9% w/w, 9.5% w/w, or 10% w/w.
The composition may further comprise an organic solvent. The organic solvent may be selected from: alkylacetates, arylacetates, alcohols (including primary, secondary and/or tertiary alcohols), carboxylic acids, ethers, ketones, alkanes, hydrocarbons (aliphatic, nitrated and chlorinated hydrocarbons), amine, esters, terpenoids, and mixtures thereof. For example, the organic solvent may be selected from: butyl acetate, ethyl acetate, ethanol, methanol, isopropanol, diacetone alcohol, acetone, ethanol, acetone-water mixtures, propanol, butanol, tert-butyl alcohol, diethyl ether, tetrahydrofuran, methyl ethyl ketone, benzyl alcohol, ethyl acetate-ethanol mixtures, glycol mixtures, acetic acid, lactic acid, propionic acid, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, ethylene glycol butyl ether, ethylene glycol ethyl ether, ethylene glycol methyl ether, dioxane, cyclohexanone, amyl alcohol, sec-butyl alcohol, iso-butyl carbinol, diacetone alcohol, citronellol, and mixtures thereof.
In one embodiment the composition described herein further comprises a polymer base.
The polymer base may comprise one or more of: a polymer, an organic solvent, a plasticizer, a dye or pigment, an adhesive, a bulking agent, a thickening agent, emulsion polymers, and mixtures thereof.
In one embodiment, the polymer base comprises at least one polymer, which may be a homo polymer or a copolymer. In another embodiment the polymer is suitable for forming a fdm. For example, the composition may comprise a polymer and forms a fdm
after initially being applied to at least a portion of a surface on an article in a non-solid form, for example as a spray or as a liquid.
The polymer base may comprise one or more polymers, for example: a polymer comprising cellulose, a polyurethane, polyethylene terephthalate, an epoxy resin, a vinyl ester, a phenolic polymer, an acrylic ester, an acrylate homopolymer or copolymer, a latex paint, a polyester, and mixtures thereof.
In one embodiment at least one polymer comprises a cellulose, optionally selected from one or more of: nitrocellulose, cellulose acetate, cellulose acetate butyrate, ethyl cellulose, alkyd resin, and mixtures thereof.
The polymer base may comprise one or more organic solvents, optionally selected from: alkylacetates, arylacetates, alcohols (including primary, secondary and/or tertiary alcohols), carboxylic acids, ethers, ketones, alkanes, hydrocarbons (aliphatic, nitrated and chlorinated hydrocarbons), amine, esters, terpenoids, and mixtures thereof. The organic solvent may be optionally selected from: butyl acetate, ethyl acetate, ethanol, methanol, isopropanol, diacetone alcohol, acetone, ethanol, acetone-water mixtures, propanol, butanol, tert-butyl alcohol, diethyl ether, tetrahydrofuran, methyl ethyl ketone, benzyl alcohol, ethyl acetate-ethanol mixtures, glycol mixtures, acetic acid, lactic acid, propionic acid, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, ethylene glycol butyl ether, ethylene glycol ethyl ether, ethylene glycol methyl ether, dioxane, cyclohexanone, amyl alcohol, sec-butyl alcohol, iso-butyl carbinol, diacetone alcohol, citronellol, and mixtures thereof.
The polymer base may comprise one or more plasticizers, optionally selected from: phthalates, dibutyl phthalate, a citrate, tributyl acetyl citrate, ethyl toluene sulfonamide (ethyl tosylamide), n-cyclohexyl para-toluene sulfonamide, glycerol, a glycol, glycol ethers, glycol esters, hydrogenated castor oil or an epoxidized oil, polyesters, polybutylenes, aliphatic polyurethanes (optionally with a molecular wright of about 2000 to about 5000), toluene sulfonamide urea formaldehyde, y-butyral lactone, n- butylphthalimide/isopropylphthalimide, ethylhexyl diphenyl phosphate, wool fat derivatives, chlorinated paraffins, glyceryl triacetate, camphor, sucrose acetate isobutyrate (SAIB), and mixtures thereof.
The polymer base may comprise one or more dyes known in the art and mixtures thereof.
The polymer base may comprise one or more adhesives, optionally in the form of a polymer, optionally selected from: tosylamide-formaldehyde resin, alkyd resin or another polymer known in the art, and mixtures thereof.
The polymer base may comprise one or more thickening agents and/or bulking agents, optionally selected from: fluorphlogopite (for example synthetic fluorphlogopite) which comprises magnesium aluminium silicate and potassium, an aluminium borosilicate, for example calcium aluminium borosilicate, stearalkonium bentonite, stearalkonium hectorite, and mixtures thereof.
In one embodiment, the polymer base is formulated as a nail polish.
In another embodiment, the composition may comprise one or more additives, for example an additive optionally selected from: iodine, benzalkonium chloride, graphene oxide, and mixtures thereof.
Herein the compositions may or may not be cross-linked. In one embodiment the composition is cross-linked. In another embodiment the composition is not cross-linked. One potential advantage obtained from the crosslinking of a composition, film or coating is the stability of the resulting materials, for example crosslinking can reduce the solubility of the coating in comparison to similar compositions which are not crosslinked. In addition, the cross-linked nature of a coating may increase the chemical resistance of the composition. The application of a cross-linked polymer to a surface of an article, may also yield a surface which has an increased heat tolerance, decreased permeability, improved abrasion resistance and/or extend the life of the article.
In one embodiment the composition may be removed from an article, or portion thereof, by the application of at least one solvent optionally selected from: alkylacetates, arylacetates, alcohols (including primary, secondary and/or tertiary alcohols), carboxylic acids, ethers, ketones, alkanes, hydrocarbons (aliphatic, nitrated and chlorinated hydrocarbons), amine, esters, terpenoids, and mixtures thereof. For example, the composition may be removed by the application of an organic solvent optionally selected from: butyl acetate, ethyl acetate, ethanol, methanol, isopropanol, diacetone alcohol, acetone, ethanol, acetone-water mixtures, propanol, butanol, tert-butyl alcohol, diethyl ether, tetrahydrofuran, methyl ethyl ketone, benzyl alcohol, ethyl acetate-ethanol mixtures, glycol mixtures, acetic acid, lactic acid, propionic acid, diethylene glycol butyl ether, diethylene glycol ethyl ether, diethylene glycol methyl ether, ethylene glycol butyl ether, ethylene glycol ethyl ether, ethylene glycol methyl ether, dioxane, cyclohexanone, amyl alcohol, sec-butyl alcohol, iso-butyl carbinol, diacetone alcohol, citronellol, and mixtures thereof.
The composition may be a synergistic composition. As used herein, the term "synergistic" refers to a greater than additive effect that is produced by a combination of compounds selected from: (i) at least one essential oil; (ii) at least one metal species; and
(iii) at least one cationic species, which exceeds the effect that would otherwise result from use of one or more of (i) to (iii).
Substrate/Article
Herein an article defined herein could be a substrate. Herein the substrate could be an inert surface or it could comprise functional groups on at least one surface thereon, which can be used to anchor or immobilise a composition such as a coating.
The composition, film or coating may be immobilised on a variety of different substrates. Examples of suitable substrate materials include, but are not limited to: metals, ceramics, glass, polymers (such as plastics), materials of biological origin, woven and non-woven fibres, inert materials such as silicon, and combinations thereof. In one embodiment the substrate is selected from the group consisting of: plastics, metals, ceramics, woven materials, silicon materials, and combinations thereof
The composition, film or coating may utilise premade polymers that are covalently attached to the surface and cross-linked. Multifunctional cross-linkers allow both attachment to the surface and crosslinking between the components of polymer, which can provide the low fouling properties.
Suitable metallic materials which may act as substrates include, but are not limited to: metals and alloys based on titanium, such as unalloyed titanium (ASTM F67) and titanium alloys, such as ASTM Fl 108, Ti-6A1-4V ELI (ASTM F136), Nitinol (ASTM F2063), nickel titanium alloys, and thermo-memory alloy materials; stainless steel (such as ASTM F138 and F139), tantalum (such as ASTM F560), palladium, zirconium, niobium, molybdenum, nickel-chrome, or certain cobalt alloys including Stellite, cobaltchromium (such as Vitallium, ASTM F75 and Wrought cobalt-chromium (ASTM F90)), and cobalt-chromium-nickel alloys (such as ELGILOY® and PHYNOX®).
Suitable ceramics which may act as substrates include, but are not limited to: oxides, carbides, or nitrides of the transition elements such as titanium oxides, hafnium oxides, iridium oxides, chromium oxides, aluminium oxides, and zirconium oxides. Silicon based materials, such as silica, may also be used.
Suitable polymer substrates include, but are not limited to: polystyrene and substituted polystyrenes, polyalkylenes, such as polyethylene and polypropylene, poly(urethane)s, polyacrylates and polymethacrylates, polyacrylamides and polymethacrylamides, polyesters (for example DACRON®), polysiloxanes, poly -ethers, poly(orthoesters), poly(carbonates), poly(hydroxyalkanoate)s, polyfluorocarbons (for example polytetrafluoroethylene), polyether ether ketone (PEEK), parylene based
polymers, dopamine based polymers, hydrogen cyanide derived polymers (aminomalononitrile), silicones, epoxy resins, polyalkenes, phenolic resins, aromatic polyamides, natural and synthetic elastomers, adhesives and sealants, polyolefins, polysulfones, polyacrylonitrile, biopolymers such as polysaccharides and natural latex copolymers thereof, and combinations thereof.
The composition, film or coating may also be immobilised on to industrial or residential or other common substrates to prevent mildew, bacterial contamination, and in other applications where it is desirable to prevent fouling, such as: marine applications (ship hull coatings), fuel tanks, oil pipelines, industrial piping, pharmaceutical equipment, drug delivery devices such as inhalers, contact lenses, dental implants, coatings for in vivo sensors, textiles such as hospital drapes, gowns, or bedding, ventilation conduits, doorknobs, devices for separations, such as membranes for microbial suspension, biomolecule separation, protein fractionation, cell separation, waste water treatment, water purification, bioreactors, and food processing.
These compositions or coatings may also be used to coat and thus treat surfaces of fibres, particulates and films for the applications of textiles, additives, electric/optical appliances, packaging materials and colorants/inks.
Applications
In one embodiment, the composition is formulated to form a film or coating. The composition may be applied in any form known in the art, on to at least a portion of a surface of an article. For example, the composition may be formulated to be applied as a spray, as a paint, as a liquid, or incorporated into a device such a sleeve for a door handle, an adhesive cover, a protective covering, such as a film.
In one embodiment, the composition is formulated to provide an antipathogenic composition, film or coating. In another embodiment, the composition is suitable for controlling, preventing and/or reducing the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
In one embodiment, the composition is an antibacterial, antifungal, and/or antiviral composition, film or coating.
In one embodiment, the composition is an antibacterial, antifungal, and/or antiviral composition, film or coating, and controls, reduces and/or eliminates at least one pathogen, and displays an efficacy for the at least one pathogen for about, or at least about: 1 day, 2 days, 3 days, 4 days, 5 days, 10 days, 15 days, 20 days, 25 days, 30 days, 35 days, 40 days, 45 days, 50 days, 55 days, or 60 days.
In one embodiment, the composition is an antibacterial composition, film or coating. In another embodiment, the composition is an antibacterial composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a bacteria selected from, but not limited to: gram-negative bacteria, gram-positive bacteria, and mixtures thereof. In yet another embodiment, the composition is an antibacterial composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a bacteria selected from: Pseudomonas aeruginosa, Staphylococcus aureus, and mixtures thereof.
In one embodiment, the composition is an antifungal composition, film or coating.
In one embodiment, the composition is suitable for controlling, preventing and/or reducing the concentration of a fungus, mildew, mould and mixtures thereof.
In one embodiment, the composition is an antiviral composition, film or coating. In another embodiment, the composition is an antiviral composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a virus selected from: an enveloped virus, a non-enveloped virus, and mixtures thereof. In yet another embodiment, the composition is an antiviral composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a virus selected from: SARS-CoV-2, or a surrogate of SARS-CoV-2, and mixtures thereof.
The Therapeutic Goods Administration of Australia recognises Murine Hepatitis Virus MHV-1 as a surrogate for COVID-19.
In one embodiment the composition is formulated as an antifouling composition, film or coating.
In one embodiment the composition is formulated for an in vivo application, for example a coating for a medical device such as a catheter or an implant.
In one embodiment, the composition is antipathogenic, optionally in the form of a coating, wherein the efficacy of the composition provides a reduction in the concentration of at least one pathogen, in a time scale of less than about, or about: 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 90 minutes, 120 minutes, or 180 minutes. A reduction in the concentration of at least one pathogen may be a reduction of about, or at least about: 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.5%, or 99.9%, of the original concentration of the pathogen.
In one embodiment, the composition is an antipathogenic composition, optionally in the form of a film or coating (for example as shown in Figure 1), wherein the
antibacterial, antifungal and/or antiviral efficacy of the composition provides a reduction in the concentration of at least one pathogen (for example a bacteria, virus and/or fungus), in a time scale of less than about, or about: 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, 60 minutes, 90 minutes, 120 minutes, or 180 minutes. A reduction in the concentration of a pathogen, such as one or more bacteria, virus and/or fungus, may be a reduction of about, or at least about: 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, 99.5%, or 99.9%, of the original concentration of the pathogen.
The composition described herein may be formulated to be applied to at least a portion of a surface of an article. The article may comprise or may be composed of a material selected from: wood, metal, plastic, and mixtures thereof.
The compositions described herein may comprise one or more film formers. Herein a polymer base may comprise one or more film formers. A film former is a compound (or a mixture of compounds), that is capable of leaving a cohesive film or coating on a surface. The film or coating may be pliable. One or more film formers may comprise a cellulose and/or one or more polymers. Examples of polymers include, but are not limited to: acrylate copolymers, for example those obtained by emulsion polymerisation, for example, acrylate/Ci2-22 methacrylate copolymers polymerised from monomers of methacrylic acid, methyl methacrylate, butyl acrylate, and cetyl-eicosiyl methacrylate; and PPG-17/isophorone diisocyanate (IPDI)/dimethylol propionic acid (DMPA) copolymer; polyurethane polymer dispersions, for example Polyurethane-34 which is a sodium salt of polymerized monomers of adipic acid, 1,6-hexandiol, neopentyl glycol, hexamethylene diisocyanate, ethylene diamine, N-(2-aminoethyl)- 3 aminoethane sulphonic acid; Polyurethane -32 which is a sodium salt of polymerized monomers of polytetramethylene glycol, hexamethylene diisocyanate, (IPDI), ethylene diamine, N-(2-aminoethyl)-3-aminoethanesulphonic acid; Polyurethane-35 which is a sodium salt of polymerized monomers of adipic acid, 1,6-hexandiol, neopentyl glycol, dicyclohexylmethane diisocyanate, ethylene diamine, N-(2-aminoethyl)- 3 aminoethane sulphonic acid; and Polyurethane-48 which is a sodium salt of polymerized monomers of adipic acid, 1,6-hexandiol, neopentyl glycol, isophorone diisocyanate, isophorone diamine, N-(2-aminoethyl)-3-aminoethanesulphonic acid; vinylpyrrolidone (VP) and polyvinylpyrrolidone (PVP) crosspolymers, copolymers and/or interpolymers such as hydrolyzed wheat protein/PVP crosspolymers; maltodextrin/VP copolymer; butylated/PVP copolymer; VP/polycarbamylpolyglycol ester;
VP/dimethylaminoethylmethacrylate/polycarbamyl polyglycol ester; and VP/dimethiconylacrylate/ polycarbamyl polyglycol ester; and mixtures thereof.
Herein the composition may comprise one or more polyester copolymers, which may be fdm formers, such as those derived from diols, for example branched alkylene diols, for example, neopentyl glycol, and alkane diacids, such as adipic acid, alkane polyacids, or alkane or aryl acid anhydrides, such as trimellitic anhydride.
Herein the composition may form a film. The composition may be in the form of a coating. In one embodiment the components of the composition for a homogenous mixture, or substantially homogenous mixture that can be applied to an article, or a portion thereof (such as a one or more surfaces of the article). In one embodiment the components of the composition can be applied to an article for forming a film.
Herein a film or coating formed from a composition defined herein, may be formed by a polymerisation reaction and/or drying.
Herein the composition may be formulated for use or application on a “high contact surface” or “high contact article”. Herein the high contact surface” or “high contact article” may be a surface that is touched repeatedly by one individual or a plurality of different individuals, and more particularly a surface that is touched repeatedly in a short space of time, such as within 30 minutes, 10 minutes, 5 minutes or sub 1 minute intervals. Examples of such high contact surfaces include, but are not limited to door handles, petrol bowser handles, touchscreens or touchpads, particularly including those in public areas, such as payment terminals, ATMs, elevator buttons, light switches, kiosk / vending machine input buttons, or similar, keyboards, user input devices, such as a mouse, the like. However, it will be appreciated that this is not essential and the techniques described herein can be applied to a wide range of different contact surfaces and/or articles.
The composition may be formulated so that it can be applied to at least a portion of a surface, for example a high contact surface.
The composition may be formulated so that it can be applied to at least a portion of a surface of an article selected from: a table, a door, a door handle, or a mixture thereof. For example, the composition may be formulated to be applied to at least a portion of a surface of an article as a liquid composition, such as a paint or as a spray, or another form such as a paste, gel or an aerosol, which then dries to form a solid, for example a film. The composition (for example initially in the form of a liquid), may be formulated to dry in about, or less than about: 30 seconds, 1 minute, 2 minutes, 3 minutes, 4 minutes, 5
minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes, or 60 minutes.
In one embodiment, the composition is formulated to form a fdm or coating in a time in a range of about 1 minute to about 60 minutes, for example: about 1 minute to about 50 minutes, about 1 minute to about 40 minutes, about 1 minute to about 30 minutes, about 1 minute to about 20 minutes, about 1 minute to about 15 minutes, about 1 minute to about 10 minutes, or about 1 minute to about 5 minutes.
Disclosed herein is a method of controlling, preventing and/or reducing the concentration of at least one pathogen, optionally selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof, the method comprising applying the composition as defined herein to at least a portion of a surface of an article.
Also disclosed herein is the use of a composition as defined herein, to control, prevent and/or reduce the concentration of at least one pathogen, optionally selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
Also disclosed herein is the use of a composition as defined herein, in the formation of an antipathogenic film.
Also disclosed herein is the use of a composition as defined herein, as an antifouling composition, film or coating.
It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the above-described embodiments, without departing from the broad general scope of the present disclosure. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.
EXAMPLE EMBODIMENTS
The present disclosure may rely on one or more of the following example embodiments.
1. A composition capable of forming an antipathogenic composition, film or coating, the composition comprising: at least one essential oil; at least one metal species; and at least one cationic species.
2. The composition of example embodiment 1, where the composition is in the form of a film or a coating.
3. The composition of example embodiment 1 or example embodiment 2, further comprising a polymer base, wherein the polymer base comprises one or more polymers and optionally one or more film formers.
4. The composition of example embodiment 3, wherein the one or more polymers are suitable for forming a film.
5. The composition of any one of example embodiments 2 to 4, wherein the polymer base comprises: a polymer comprising: a cellulose, a polyurethane, polyethylene terephthalate, an acrylate homopolymer or copolymer, and mixtures thereof.
6. The composition of example embodiment 5, wherein the cellulose is selected from one or more of: nitrocellulose, cellulose acetate, cellulose acetate butyrate, ethyl cellulose, and mixtures thereof.
7. The composition of any one of the preceding example embodiments, wherein the at least one essential oil is selected from or an extract of: cloves, thyme, fennel, caraway, peppermint, lemon myrtle, tea tree, thymol, carvacrol, eugenol, menthol, terpineol, carvone, citral, or mixtures thereof.
8. The composition of any one of the preceding example embodiments, wherein the at least one essential oil is selected from: cinnamaldehyde, tea tree oil, carvacrol, or mixtures thereof.
9. The composition of any one of the preceding example embodiments, wherein the at least one metal species comprises at least one elemental metal.
10. The composition of any one of the preceding example embodiments, wherein the at least one metal species comprises at least one metal selected from: copper, silver, titanium aluminium, cobalt, gold, lead, magnesium, molybdenum, nickel, tin, zinc, zirconium, compounds thereof, salts thereof, oxides thereof, complexes thereof, mixtures thereof, and alloys thereof.
11. The composition of any one of the preceding example embodiments, wherein the at least one metal species is a salt.
12. The composition of any one of example embodiments 1 to 10, wherein the at least one metal species is an oxide.
13. The composition of any one of example embodiments 1 to 10, wherein the at least one metal species is an oxide selected from: copper oxide, titanium oxide, and mixtures thereof.
14. The composition of any one of example embodiments 1 to 10, wherein the at least one metal species is a mixture of metals.
15. The composition of any one of example embodiment 1 to 10, wherein the at least one metal species is an alloy.
16. The composition of any one of the preceding example embodiments, wherein the at least one metal species is a powder.
17. The composition of any one of the preceding example embodiments, wherein the at least one metal species is a particle or a colloid.
18. The composition of any one of the preceding example embodiments, wherein the at least one metal species is a coated particle, optionally a metal particle comprising a mixture of metals.
19. The composition of any one of the preceding example embodiments, wherein at least one metal species is replaced with a transition element, or a salt, oxide or complex thereof.
20. The composition of any one of the preceding example embodiments, wherein the at least one metal species is a particle with a mean diameter of about 50 nm to about 100 nm.
21. The composition of any one of the preceding example embodiments, wherein the cationic species is a polymer.
22. The composition of any one of the preceding example embodiments, wherein the cationic species is a cationic polymer and comprises one or more monomers selected from: lysine, hexamethylene guanidine, and mixtures thereof.
23. The composition of any one of the preceding example embodiments, wherein the cationic species is a cationic polymer and cationic polymer is a salt, optionally a chloride salt.
24. The composition of any one of the preceding example embodiments, wherein the cationic species is a cationic polymer and cationic polymer is a homopolymer.
25. The composition of any one of example embodiments 1 to 23, wherein the cationic species is a cationic polymer and the cationic polymer is a copolymer.
26. The composition of any one of the preceding example embodiments, wherein one or more of: the at least one essential oil; the at least one metal species and/or the at least one cationic species, is present in a range of about 0.05% w/w to about 10% w/w.
27. The composition of any one of the preceding example embodiments, wherein the composition further comprises an organic solvent selected from: alkylacetates, arylacetates, alcohols (including primary, secondary and/or tertiary alcohols), carboxylic acids, ethers, ketones, alkanes, hydrocarbons (optionally aliphatic, nitrated and chlorinated hydrocarbons), amine, esters, terpenoids, and mixtures thereof.
28. The composition of the preceding example embodiments, further comprising an organic solvent selected from: butyl acetate, ethyl acetate, ethyl alcohol, isopropanol, diacetone alcohol, acetone, and mixtures thereof.
29. The composition of any one of the preceding example embodiments, wherein the polymer base further comprises one or more of: an organic solvent, a plasticizer, a dye or pigment, an adhesive, a bulking agent, a thickening agent, and mixtures thereof.
30. The composition of example embodiment 29, wherein the organic solvent is selected from: alkylacetates, arylacetates, alcohols, ethers, ketones, alkanes, hydrocarbons, and mixtures thereof.
31. The composition of example embodiment 29 or example embodiment 30, wherein the organic solvent is selected from: butyl acetate, ethyl acetate, ethyl alcohol, isopropanol, diacetone alcohol, and mixtures thereof.
32. The composition of any one of example embodiments 29 to 31, wherein the plasticizer is selected from: phthalates, dibutyl phthalate, a citrate, tributyl acetyl citrate, ethyl toluene sulfonamide (ethyl tosylamide), n-cyclohexyl para-toluene sulfonamide, glycerol, a glycol, glycol ethers, glycol esters, hydrogenated castor oil or an epoxidized oil, polyesters, polybutylenes, aliphatic polyurethanes (optionally with a molecular wright of about 2000 to about 5000), toluene sulfonamide urea formaldehyde, y-butyral lactone, n-butylphthalimide/isopropylphthalimide, ethylhexyl diphenyl phosphate, wool fat derivatives, chlorinated paraffins, glyceryl triacetate, camphor, sucrose acetate isobutyrate (SAIB), and mixtures thereof.
33. The composition of any one of example embodiments 29 to 32, wherein the adhesive is a polymer, optionally selected from tosylamide-formaldehyde resin.
34. The composition of any one of example embodiments 29 to 33, wherein the bulking agent and/or the thickening agent is selected from: fluorphlogopite, an aluminium borosilicate, optionally calcium aluminium borosilicate, stearalkonium bentonite, stearalkonium hectorite, and mixtures thereof.
35. The composition of any one of the preceding example embodiments, wherein the polymer base is formulated as a nail polish.
36. The composition of any one of the preceding example embodiments, wherein the composition is formulated as a liquid or aerosol to form a film or coating.
37. The composition of any one of the preceding example embodiments wherein the composition is formulated for slow release, optionally over a period of about, or at least about: 1 day, 2 days, 3 days, 4 days, 5 days, 10 days, 15 days, 20 days, 25 days, 30 days,
35 days, 40 days, 45 days, 50 days, 55 days, 60 days, 65 days, 70 days, 75 days, 80 days, 85 days, 90 days, 95 days, 100 days, 105 days, 110 days, 115 days, or 120 days.
38. The composition of any one of the preceding example embodiments wherein the composition is formulated for the slow release of one or more of (i) to (iii), over a period of about, or at least about: 1 day, 2 days, 3 days, 4 days, 5 days, 10 days, 15 days, 20 days, 25 days, 30 days, 35 days, 40 days, 45 days, 50 days, 55 days, 60 days, 65 days, 70 days, 75 days, 80 days, 85 days, 90 days, 95 days, 100 days, 105 days, 110 days, 115 days, or 120 days.
39. The composition of any one of the preceding example embodiments wherein the composition is formulated such that the composition displays efficacy against at least one pathogen following the application of an aqueous solvent.
40. The compositions of example embodiment 39, wherein the aqueous solvent comprises sweat.
41. The composition of any one of the preceding example embodiments, wherein the composition is formulated to be applied as a spray, as a paint, as a liquid, a paste, a gel or an aerosol.
42. The composition of any one of the preceding example embodiments, wherein the composition is in the form of an antipathogenic film or coating.
43. The composition of any one of the preceding example embodiments, wherein the composition is suitable for controlling, preventing and/or reducing the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
44. The composition of any one of the preceding example embodiments, wherein the composition is an antibacterial composition, film or coating.
45. The composition of any one of the preceding example embodiments, wherein the composition is an antifungal composition, film or coating
46. The composition of example embodiment 45, wherein the composition is suitable for controlling, preventing and/or reducing the concentration of a fungi, mildew, mould or a mixture thereof.
47. The composition of any one of the preceding example embodiments, wherein the composition is an antibacterial composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a bacteria selected from: Gram-negative bacteria, Gram-positive bacteria, and mixtures thereof.
48. The composition of any one of the preceding example embodiments, wherein the composition is an antibacterial composition, fdm or coating suitable for controlling, preventing and/or reducing the concentration of a bacteria selected from: Pseudomonas aeruginosa, Staphylococcus aureus, and mixtures thereof.
49. The composition of any one of the preceding example embodiments, wherein the composition is an antiviral composition, fdm or coating.
50. The composition of any one of the preceding example embodiments, wherein the composition is an antiviral composition, fdm or coating suitable for controlling, preventing and/or reducing the concentration of a virus selected from: an enveloped virus, a non-enveloped virus, and mixtures thereof.
51. The composition of any one of the preceding example embodiments, wherein the composition is an antiviral composition, fdm or coating suitable for controlling, preventing and/or reducing the concentration of a virus selected from: SARS-CoV-2, or a surrogate thereof, influenza, and mixtures thereof.
52. The composition of any one of the preceding example embodiments, wherein the composition is an antibacterial, antifungal, and/or antiviral composition, fdm or coating.
53. The composition of any one of the preceding example embodiments, wherein the composition is formulated as an antifouling composition, fdm or coating.
54. The composition of any one of the preceding example embodiments, wherein the composition is an antipathogenic composition, fdm or coating which displays efficacy against at least one pathogen for at least about: 5, 10, 15, 20, 25 or 30 days.
55. The composition of any one of the preceding example embodiments, further comprising at least one other component, optionally selected from: iodine, graphene oxide, and mixtures thereof.
56. The composition of any one of the preceding example embodiments, wherein the composition is formulated to be applied to at least a portion of a surface of an article.
57. The composition of example embodiment 56, wherein the article comprises or is composed of a material selected from: wood, metal, plastic, and mixtures thereof.
58. The composition of any one of the preceding example embodiments, wherein the composition is formulated to be applied to at least a portion of a surface of an article selected from: a table, a door, a door handle, or a mixture thereof.
59. The composition of any one of the preceding example embodiments, wherein the composition is formulated to be applied to at least a portion of a surface of an article as a liquid composition, solid composition or gaseous composition.
60. The composition of example embodiment 59, wherein the liquid composition, solid composition or gaseous composition, is formulated to dry in less than about: 5, 10, 15, 20, 25, or 30 minutes.
61. The composition of any one of the preceding example embodiments, wherein the composition is formulated for an in vivo application.
62. The composition of any one of the preceding example embodiments, wherein the composition is formulated for an in vivo application for a medical device, optionally selected from a catheter or an implant.
63. A coating or fdm comprising the composition of any one of the preceding example embodiments.
64. A method of controlling, preventing and/or reducing the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof, the method comprising applying the composition of any one of example embodiments 1 to 62, to at least a portion of a surface of an article.
65. Use of a composition of any one of example embodiments 1 to 62, to control, prevent and/or reduce the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
66. Use of a composition of any one of example embodiments 1 to 62 in the formation of an antipathogenic composition, fdm or coating.
67. Use of a composition of any one of example embodiments 1 to 62, as an antifouling composition, fdm or coating.
EXAMPLES
Example 1 - Antimicrobial Activity
Materials
A commercial nail polish formulation was used to incorporate compounds with anti-pathogen properties and to produce coatings. Poly E-L-lysine HC1 (MW 3,500- 5,000Da) and polyhexamethylene guanidine obtained from Biosynth Carbosynth®. Cinnamaldehyde, carvacrol, copper (II) oxide (nanopowder <50nm particle size (TEM)), silver and copper nanoparticles were acquired from Sigma-Aldrich. Tea tree oil was purchased from Thursday Plantation. Silver-coated nanoparticles were obtained from Nanoshel containing copper 80% silver 20%, size 80-100 nm, purity 99.9%. Nutrient agar, Mueller-Hinton broth and sterile fdter paper were purchased form ThermoFisher
Scientific (Oxoid). Aluminium discs were laser cut to various sizes and were used as substrates in the different assays.
Bacterial Strains and Growth Conditions
Gram-negative Pseudomonas aeruginosa ATCC 27853 and Gram-positive Staphylococcus aureus ATCC 25923 strains were employed. Bacterial stocks were prepared in 60% glycerol and stored at -80 °C until needed. All surfaces were sterilized with UV prior to the bacterial assay.
Coatings Fabrication
For 2.5% two or three component mixtures, 25 mg of each component and 300 pL ethyl acetate were added to a vial per mb of the polymer formulation before thorough mixing with a spatula. For the 5% single component systems 50 mg of each component and 200 pL of ethyl acetate were added to a vial per mb of polymer paint mixture. This was mixed thoroughly with a spatula. The compositions were painted on the sides and edges, or bottom and sides of various substrates of 96 well plates. If the paint became overly viscous a few drops of ethyl acetate was added to allow the composition to be applied. Samples were painted within an aura 2000 M.A.C. biohazard cabinet. After allowing at least 3 hours or overnight dry, samples were UV treated within the cabinet for 20 minutes, turned over then UV treated again.
X-ray Photoelectron Spectroscopy
X-ray photoelectron spectroscopy (XPS) analysis was used to characterize the surface chemistry (surface elemental composition) of the coatings. XPS analysis was performed using an AXIS Ultra-DUD spectrometer (Kratos Analytical Utd, U.K.) equipped with a monochromated Al-Ka X-ray source at a power of 180 W (12 mA, 15 kV). An internal electron flood gun was used to compensate for sample charging during irradiation. All elements presented were identified from low resolution survey spectra (acquired at a pass energy of 160 eV). The atomic concentrations of the detected elements were calculated using integral peak intensities and the sensitivity factors supplied by the manufacturer. Data processing was performed using CasaXPS processing software version 2.3.21(Casa Software Utd., Teignmouth, United Kingdom).
Antimicrobial Susceptibility Assays
Zone of inhibition assay
Bacterial stocks were streaked onto nutrient agar plates to be used as working stock. After 24 hours incubation at 37 °C, a single colony from the streaked plate was
used and inoculate in 10 mL of Mueller-Hinton broth (MHB) which was incubated overnight (180 rpm) at 37 °C. This culture was further diluted in MHB to obtain 106 colony-forming units per mL (cfu mL-1). Cultures were spread evenly onto agar plates using a sterile swab. Sterile fdter paper discs (6 mm 0 - Oxoid antimicrobial susceptibility test discs) previously coated with mixtures of the polymeric formulation and individual antimicrobial compounds at 5% concentration were gently pressed onto the surface of the agar plates. Discs coated with the polymeric fdm alone were used as controls. Plates were then inverted and incubated for approximately 24hours at 37 °C and the diameter of the inhibition zones was measured in mm, including the diameter of the disc.
Crystal violet assay
The bottom and walls of the wells in a 96 well plate were painted with a combination of two antimicrobial compounds and the polymeric formulation and dry overnight inside the biohazard cabinet. One hundred microlitres of the diluted bacterial suspensions (106 cfu mL-1) were pipetted into each well and incubate for 24 hours at 37 °C with gentle agitation (75 rpm). After overnight incubation, the cell suspensions were carefully removed, and the wells were rinsed twice with 110 pl of PBS per well to remove non-adherent cells. To quantify biofdm biomass formed on the surface of the coatings, the plates were heat-fixed in a 60 °C oven for 1 hour and then stained with 100 pl of 1% (w/v) crystal violet for 10 minutes. The crystal violet was removed, and the plates were washed three times by immersing them in cold water to remove excess stain. Excess water after washing was removed by gently tapping the plates against paper towels. One hundred microliters of 95% ethanol were added to each well and the plate was incubated at room temperature for 10 minutes. One hundred microliters of solution from each well were transferred into a new plate. The biomass of biofilm from each well was determined by reading the optical density using a BioTek plate reader at 600 nm.
Biofilm experiments
For biofilm experiments, bacterial stocks were streaked onto nutrient agar plates to be used as working stock. After 24 hours incubation at 37 °C, a single colony from the streaked plate was used and inoculate in 10 mL of MHB which was incubated overnight (180 rpm) at 37 °C. For the biofilm test, aluminium disks (6 mm 0 laser cut aluminium round discs) with both sides coated with the specific antipathogen combination were incubated for 24 hours at 37 °C with 50 pL of bacteria solution (106 cfu mL-1). After incubation samples were gently washed 3 times using sterile phosphate buffered saline (PBS) to remove any planktonic cell. The samples were individually transferred to a
sterile Eppendorf tube containing ImL of sterile PBS. Samples were vortexed (3 times as 30 seconds) and sonicated for 10 minutes to detach bacterial biofdm from the surface. After sonication, samples were vortex again for 30 seconds. The suspensions obtained were serially diluted and aliquots of 20 pL were plated on nutrient agar plates for viable counts.
Results and Discussion
Homogeneous mixtures of individual compounds and the polymeric formulation were fabricated. Filter papers were coated with each mixture and the antimicrobial activity was evaluated via the zone of inhibition test.
In vitro antibacterial activity of each individual compound against both Grampositive and Gram negative bacteria was assessed via the zone of inhibition test (Figure 2 and Figure 3). The cationic polymers PHMB and s-PL showed antibacterial effects on both bacteria (Figure 2G-H and Figure 3G-H). Structural characteristics of the external layer of Gram-negative bacteria particularly its thickness and composition (lipoprotein, lipid bilayer and endotoxin) confer more protection against antimicrobial agents when compared to Gram-positive bacteria. Essential oils such as cinnamaldehyde and carvacrol were effective against Staph, aureus with cinnamaldehyde being extremely effective (Figure 2D) with the biggest zone of inhibition of all compounds (~25 mm).
The antibacterial activity observed from the metal nanoparticles in the zone of inhibition test could be attributed to the lack of diffusion of the nanoparticles from the fdter paper disc to the agar plate or the limited solubility of the ions and other species released by the nanoparticles into the agar plate. The diffusivity of nanoparticles with sizes greater than 10 nm in culture media is expected to be in the order of 10-11 m2/s, which is lower compared to the diffusion of antibiotics commonly employed in this test.
For a second antimicrobial assay, the effect of the combination of two antimicrobial compounds was evaluated using both a semi-quantitative standard biofdm assay based on crystal violet staining (Figure 4 and Figure 5) and a quantitative biofdm 96 well-plate experiment (Figure 7). For the semi -quantitative analysis, crystal violet was incorporated after 24 hours bacterial incubation in a 96 well plate where each well was individually coated with the respective antimicrobial combination at a final concentration of 5%, 2.5% of each compound (Figure 4 and Figure 5). Optical density results showed a significant dropping in biofdm biomass growth for combinations containing cinnamaldehyde, copper oxide, silver and copper nanoparticles which was consistent for both Gram-positive and Gram-negative bacteria. The samples that showed lower biofdm mass were then employed in a 96 well plate biofdm test.
To evaluate the ability of the coatings to resist microbial biofilm formation, coated samples were subjected to a 96 well plate biofilm experiment where viable counts were assessed. Aluminium substrates of 6 mm diameter were painted on both sides each sample with different combinations of two antimicrobial compounds (Figure 6). Samples were incubated with both Gram-positive and Gram-negative bacteria for 24 hours. Then, samples were washed to remove any non-adherent planktonic bacteria followed by detachment of bacterial biofilm in PBS. Aliquots of the solution were diluted and plated on agar to evaluate bacterial viability. Colony counting of viable bacteria was attempted showing a greater reduction in the viability of Staph, aureus when combinations of cinnamaldehyde and either copper oxide or silver-coated copper nanoparticles were employed (Figure 6). Higher antibacterial activity of cinnamaldehyde against Staph, aureus compared to other bacterial strains including Gram-negative Escherichia coli has been reported. The biofilm formation by Staph, aureus has been described to be dominated by the production of polysaccharide intercellular adhesin (PIA) synthesized by icaADBC encoded proteins including the biofilm-associated protein (Bap) which is crucial for adherence and biofilm development. A study using methicillin resistant Staph, aureus (MRSA) reported that the expression of the gene SarA (a regulator of the Bap protein) can be critically affected by the presence of cinnamaldehyde at subminimum inhibitory concentrations. In terms of copper nanoparticles, although their exact mechanism of action is still unclear, some studies have proposed cytoplasm membrane damage due to the affinity of copper nanoparticles to amines and carboxyl groups present at the cell surface of some microorganisms.
From the zone of inhibition data showing the effectiveness displayed by the cationic polymers against P. aeruginosa and considering the ambiguity in the results from the cationic combinations in the crystal violet test mentioned above, a three- component antimicrobial system including the cationic polymers was evaluated. Table 1 presents the three-component combination coating for this set of experiments.
Table 1. Three components combination coatings
The three component system was then evaluated via a biofilm experiment similar to what was previously conducted with the two component coatings. All combinations showed significant activity against both Staph. Aureus and P. aeruginosa, providing a 5- log and 6-log reduction respectively (Figure 7 and Figure 8). P. aeruginosa is commonly observed during colonization and infection of for example chronic ulcers, studies in this area have suggested the use of PHMB due to its proteolysis resistance properties. This cationic polymer has been widely employed in hospitals, industries and homes as a result of its antibacterial and antiviral properties. The ability of PHMB to penetrate bacterial membrane leading to bacterial death has commonly been accepted as its mechanism of action. PHMB has been incorporated into for example polydimethylsiloxane (PDMS) films where inhibition of E. coli, Staph, aureus and Staph, epidermis among other strains has been reported at different loading concentrations (0.1, 0.3, 0.5% (w/w)). Despite the low cytotoxicity against L929 cells of the PHMB loaded samples at concentration of 0.1% in this study, other reports have revealed the likelihood of PHMB to enter mammalian cells. For the specific case of s-PL. electrostatic adsorption as a result of its cationic nature has been the recognized mechanism of action. s-PL has been widely used in food applications but recently its uses have been expanded into the medical research and industrial areas. For biomedical applications, s-PL has been grafted to methacrylamide for the fabrication of hydrogels which showed a 3 -log reduction on the counts of P aureginosa in vitro. Similarly, s-PL was cross-linked with catechol for the fabrication of antibacterial paint for medical devices. The coatings at the highest concentration of s-PL reported a 99.99% reduction in both Gram-positive and Gramnegative bacteria as well as the ability to inhibit biofilm formation for one week. When the antimicrobial properties of s-PL were evaluated against different strains of P. aeruginosa, 3 -log reduction in the viability was reported when concentrations greater than two times the minimum inhibitory concentrations were employed. Here, s-PL was reported to hold the highest microbial selectivity over mammalian cells compared to other cationic polymers such as linear polyethylenimine (LPEI), cc-poly-D-lysine (PDL) and cc-poly-L-lysine (PLL), among others.
The surface of the three compounds combination was analysed by XPS. Coatings comprised of individual and two component combinations were prepared. The XPS survey spectra of individual compounds and their combinations including cinnamaldehyde, copper oxide, s-PL and PHMB indicated the presence of oxygen, nitrogen and carbon (Table 2) mostly related to the polymeric formulation being the main component of the coating. Traces of silicon, a common contamination in XPS were observed. Interestingly, copper presence was not detected in any of the samples, it is
assumed that the dry condition of the analysis did not allow copper ions to migrate to the surface as when wet conditions are employed.
Example 2 - Antiviral efficacy
The antimicrobial compositions were tested for the inactivation of human coronavirus OC43 (Infectivity Assay 1 - component antiviral testing) and to extend the testing of the antimicrobial composition on a panel of virus consisting of OC43, 229E and RVA1 (Infectivity Assay 2 - antiviral testing on a range of viruses).
Infective Assay 1 - Antiviral Testing Using OC43
Materials and Methods
Products used:
• Single component Cu(II)O
• Single component cinnamaldehyde
• Single component lysine
• Single component PHMB
• Two component Cu(II)O and cinnamaldehyde
• Two component Cu(II)O and lysine
• Two component cinnamaldehyde and lysine
• Control nail polish labelled as C
• Three component Cu(II)O, cinnamaldehyde and lysine
• Three component Cu(II)O, cinnamaldehyde and PHMB - Labelled as PB
Protocol and Total Number of Samples
25 pL OC43 or control was applied to each material in sterile 24 well tissue culture plates. Test samples were incubated for one hour (class II BSC, lid of the plate left on).
The harvest was one hour post virus addition/media addition, virus was collected in 975 pL of TCID virus infectivity assay media (EMEM 1% FCS) and immediately transferred to a sterile 1 ,7mL tube. All samples were stored at -80 °C upon harvest, until infectivity assay.
The remaining virus inoculum was stored at -80 °C.
Results
Figure 9 shows TCID values for OC43 infectious virus after exposure to the tested compounds. PB and PHMB component showed toxicity to MRC-5 cells. The toxicity of all other component was negligible. Of the single components, the viral infectivity of OC43 was significantly lower in the cinnamaldehyde and PHMB treated discs (p<0.0005), in comparison to baseline. There was no significant reduction of OC43 infectivity for Cu(II)O and lysine treated discs after 60 minutes, however the combination of Cu(II)O with lysine resulted in a significant reduction of infectious OC43 in comparison to untreated discs (p<0.005). Similarly, infectious virus was reduced for discs treated with Cu(II)O combined with cinnamaldehyde (p<0.0005), but the reduction
was comparable to cinnamaldehyde alone. Maximum reduction in infectious virus was observed for the double component cinnamaldehyde and lysine, as well as the LY and PB treated discs (p<0.0005). For these three components, the reduction of infectious OC43 was greater than 99.9% in comparison to baseline (Table 3). In Table 3, the reduction was calculated based on averages using the following formula: 100* (baseline
- tested component)/baseline. A negative value corresponds to a reduction of infectious virus in the tested compound, in comparison to baseline.
Table 3: Percentage of reduction of OC43 infectious virus components after one hour exposure to tested components.
Infectivity Assay 2- Antiviral Testing OC43, 229E and RVA1
Materials and Methods
Products used:
• Control Nail Polish labelled as C
• Three component Cu(II)O, cinnamaldehyde and lysine - Vials labelled as LY
• Three component Cu(II)O, cinnamaldehyde and PHMB - Vials labelled as PB
Protocol
25 pL of 229E, OC43 or RV lb diluted as follow was applied to SF/baseline discs in sterile 24 well tissue culture plates. Note - updated timing'. Test samples were incubated for 30 min, 1 hour (class II BSC, lid of the plate left on):
. 229E at 4x 105 TCID50/mL (diluted in EMEM 1% FCS to give lx 104 TCID50/25 pL) = repeat from previous experiment
. OC43 at 4x 107 TCID50/mL (diluted in EMEM 1% FCS to give lx 106 TCID50/25 pL) = other virus with higher titre to increase range of antiviral testing
. RVlB 4x 107 TCID50/mL (diluted in DMEM 1% FCS to give lx 106TCID50/25 pL)
• Control wells 25uL of 1 % EMEM or 1 % DMEM was added to assess cell toxicity of the materials. Half the samples were assayed in MRC-5 (as done for coronavirus infection) and half the samples were assayed in RD ICAM (as done for rhinovirus infection)
For the harvest, at the specified time post virus addition, virus were collected in 975 pL of TCID virus infectivity assay media (EMEM 1% FCS or 1% FCS DMEM ) and immediately transferred to a sterile 1.7mL tube. All samples were stored at -80 °C upon harvest, until infectivity assay.
The remaining virus inoculum were stored at -80 °C.
Results
Figure 10 shows TCID values for OC43 infectious virus after exposure to the tested compounds and Table 4 shows corresponding reduction percentage in comparison to baseline. A cell toxicity was observed for PB treated discs in RD-ICAM cells. The toxicity of the LY component was negligible. There was no significant reduction of RV infectivity for the treated disc in comparison to baseline at 30 minutes of exposure. After one hour, the viral infectivity assay showed a significant reduction in infectious RV-A1
both for the LY (*: p<0.05; 60% reduction to baseline) and PB (**: p<0.001; 63% reduction to baseline) treated discs in comparison to untreated discs.
In Table 4, the reduction was calculated based on averages using the following formula: 100* (baseline - tested component)/baseline. A negative value corresponds to a reduction of infectious virus in the tested compound, in comparison to baseline. On the contrary, a positive value corresponds to an increase in infectious virus in the tested compounds, in comparison to baseline. Baseline at 1 hour post infection was compared to baseline infectious virus at 30 min of exposure. One technical replicate was excluded for the LY compound at 1 hour.
Claims
1. A composition capable of forming an antipathogenic film or coating, the composition comprising:
(i) at least one essential oil
(ii) at least one metal species and
(iii) at least one cationic species.
2. The composition of claim 1, where the composition is in the form of a film or a coating.
3. The composition of claim 1 or claim 2, further comprising a polymer base, wherein the polymer base comprises one or more polymers.
4. The composition of claim 3, wherein the one or more polymers are suitable for forming a film.
5. The composition of any one of claims 2 to 4, wherein the polymer base comprises: a polymer comprising: a cellulose, a polyurethane, polyethylene terephthalate, an acrylate homopolymer or copolymer, and mixtures thereof.
6. The composition of claim 5, wherein the cellulose is selected from one or more of: nitrocellulose, cellulose acetate, cellulose acetate butyrate, ethyl cellulose, and mixtures thereof.
7. The composition of any one of the preceding claims, wherein the at least one essential oil is selected from or an extract of: cloves, thyme, fennel, caraway, peppermint, lemon myrtle, tea tree, thymol, carvacrol, eugenol, menthol, terpineol, carvone, citral, or mixtures thereof.
8. The composition of any one of the preceding claims, wherein the at least one essential oil is selected from: cinnamaldehyde, tea tree oil, carvacrol, or mixtures thereof.
9. The composition of any one of the preceding claims, wherein the at least one metal species comprises at least one elemental metal.
10. The composition of any one of the preceding claims, wherein the at least one metal species comprises at least one metal selected from: copper, silver, titanium
aluminium, cobalt, gold, magnesium, molybdenum, nickel, silicon, tin, zinc, zirconium, compounds thereof, salts thereof, oxides thereof, complexes thereof, mixtures thereof, and alloys thereof.
11. The composition of any one of the preceding claims, wherein the at least one metal species is a salt.
12. The composition of any one of claims 1 to 10, wherein the at least one metal species is an oxide.
13. The composition of any one of claims 1 to 10, wherein the at least one metal species is an oxide selected from: copper oxide, titanium oxide, and mixtures thereof.
14. The composition of any one of claims 1 to 10, wherein the at least one metal species is a mixture of metals.
15. The composition of any one of claim 1 to 10, wherein the at least one metal species is an alloy.
16. The composition of any one of the preceding claims, wherein the at least one metal species is a powder.
17. The composition of any one of the preceding claims, wherein the at least one metal species is a particle or a colloid.
18. The composition of any one of the preceding claims, wherein the at least one metal species is a coated particle, optionally a metal particle comprising a mixture of metals.
19. The composition of any one of the preceding claims, wherein at least one metal species is replaced with a transition element, or a salt, oxide or complex thereof.
20. The composition of any one of the preceding claims, wherein the at least one metal species is a particle with a mean diameter of about 50 nm to about 100 nm.
21. The composition of any one of the preceding claims, wherein the cationic species is a polymer.
22. The composition of any one of the preceding claims, wherein the cationic species is a cationic polymer and comprises one or more monomers selected from: lysine, hexamethylene guanidine, and mixtures thereof.
23. The composition of any one of the preceding claims, wherein the cationic species is a cationic polymer and cationic polymer is a salt, optionally a chloride salt.
24. The composition of any one of the preceding claims, wherein the cationic species is a cationic polymer and cationic polymer is a homopolymer.
25. The composition of any one of claims 1 to 23, wherein the cationic species is a cationic polymer and the cationic polymer is a copolymer.
26. The composition of any one of the preceding claims, wherein one or more of:
(i) the at least one essential oil
(ii) the at least one metal species and/or
(iii) the at least one cationic species, is present in a range of about 0.05% w/w to about 10% w/w.
27. The composition of any one of the preceding claims, wherein the composition further comprises an organic solvent selected from: alkylacetates, arylacetates, alcohols, carboxylic acids, ethers, ketones, alkanes, hydrocarbons (optionally aliphatic, nitrated and chlorinated hydrocarbons), amine, esters, terpenoids, and mixtures thereof.
28. The composition of the preceding claims, further comprising an organic solvent selected from: butyl acetate, ethyl acetate, ethyl alcohol, isopropanol, diacetone alcohol, acetone, and mixtures thereof.
29. The composition of any one of the preceding claims, wherein the polymer base further comprises one or more of: an organic solvent, a plasticizer, a dye or pigment, an adhesive, a bulking agent, a thickening agent, and mixtures thereof.
30. The composition of claim 29, wherein the organic solvent is selected from: alkylacetates, arylacetates, alcohols, ethers, ketones, alkanes, hydrocarbons, and mixtures thereof.
31. The composition of claim 29 or claim 30, wherein the organic solvent is selected from: butyl acetate, ethyl acetate, ethyl alcohol, isopropanol, diacetone alcohol, and mixtures thereof.
32. The composition of any one of claims 29 to 31, wherein the plasticizer is selected from: phthalates, dibutyl phthalate, a citrate, tributyl acetyl citrate, ethyl toluene sulfonamide (ethyl tosylamide), n-cyclohexyl para-toluene sulfonamide, glycerol, a glycol, glycol ethers, glycol esters, hydrogenated castor oil or an epoxidized oil, polyesters, polybutylenes, aliphatic polyurethanes (optionally with a molecular wright of about 2000 to about 5000), toluene sulfonamide urea formaldehyde, y-butyral lactone, n- butylphthalimide/isopropylphthalimide, ethylhexyl diphenyl phosphate, wool fat derivatives, chlorinated paraffins, glyceryl triacetate, camphor, sucrose acetate isobutyrate (SAIB), and mixtures thereof.
33. The composition of any one of claims 29 to 32, wherein the adhesive is a polymer, optionally selected from tosylamide-formaldehyde resin.
34. The composition of any one of claims 29 to 33, wherein the bulking agent and/or the thickening agent is selected from: fluorphlogopite, an aluminium borosilicate, optionally calcium aluminium borosilicate, stearalkonium bentonite, stearalkonium hectorite, and mixtures thereof.
35. The composition of any one of the preceding claims, wherein the polymer base is formulated as a nail polish.
36. The composition of any one of the preceding claims, wherein the composition is formulated as a liquid or aerosol to form a film or coating.
37. The composition of any one of the preceding claims wherein the composition is formulated for slow release, optionally over a period of about, or at least about: 1 day, 2 days, 3 days, 4 days, 5 days, 10 days, 15 days, 20 days, 25 days, 30 days, 35 days, 40 days, 45 days, 50 days, 55 days, 60 days, 65 days, 70 days, 75 days, 80 days, 85 days, 90 days, 95 days, 100 days, 105 days, 110 days, 115 days, or 120 days.
38. The composition of any one of the preceding claims wherein the composition is formulated for the slow release of one or more of (i) to (iii), over a period of about, or at least about: 1 day, 2 days, 3 days, 4 days, 5 days, 10 days, 15 days, 20 days, 25 days, 30
days, 35 days, 40 days, 45 days, 50 days, 55 days, 60 days, 65 days, 70 days, 75 days, 80 days, 85 days, 90 days, 95 days, 100 days, 105 days, 110 days, 115 days, or 120 days.
39. The composition of any one of the preceding claims wherein the composition is formulated such that the composition displays efficacy against at least one pathogen following the application of an aqueous solvent.
40. The compositions of claim 39, wherein the aqueous solvent comprises sweat.
41. The composition of any one of the preceding claims, wherein the composition is formulated to be applied as a spray, as a paint, as a liquid, a paste, a gel or an aerosol.
42. The composition of any one of the preceding claims, wherein the composition is in the form of an antipathogenic film or coating.
43. The composition of any one of the preceding claims, wherein the composition is suitable for controlling, preventing and/or reducing the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
44. The composition of any one of the preceding claims, wherein the composition is an antibacterial composition, film or coating.
45. The composition of any one of the preceding claims, wherein the composition is an antifungal composition, film or coating
46. The composition of claim 45, wherein the composition is suitable for controlling, preventing and/or reducing the concentration of a fungi, mildew, mould or a mixture thereof.
47. The composition of any one of the preceding claims, wherein the composition is an antibacterial composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a bacteria selected from: Gram-negative bacteria, Grampositive bacteria, and mixtures thereof.
48. The composition of any one of the preceding claims, wherein the composition is an antibacterial composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a bacteria selected from: Pseudomonas aeruginosa, Staphylococcus aureus, and mixtures thereof.
49. The composition of any one of the preceding claims, wherein the composition is an antiviral composition, film or coating.
50. The composition of any one of the preceding claims, wherein the composition is an antiviral composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a virus selected from: an enveloped virus, a non-enveloped virus, and mixtures thereof.
51. The composition of any one of the preceding claims, wherein the composition is an antiviral composition, film or coating suitable for controlling, preventing and/or reducing the concentration of a virus selected from: SARS-CoV-2, or a surrogate thereof, influenza, and mixtures thereof.
52. The composition of any one of the preceding claims, wherein the composition is an antibacterial, antifungal, and/or antiviral composition, film or coating.
53. The composition of any one of the preceding claims, wherein the composition is formulated as an antifouling composition, film or coating.
54. The composition of any one of the preceding claims, wherein the composition is an antipathogenic composition, film or coating which displays efficacy against at least one pathogen for at least about: 5, 10, 15, 20, 25 or 30 days.
55. The composition of any one of the preceding claims, further comprising at least one other component, optionally selected from: iodine, graphene oxide, and mixtures thereof.
56. The composition of any one of the preceding claims, wherein the composition is formulated to be applied to at least a portion of a surface of an article.
57. The composition of claim 56, wherein the article comprises or is composed of a material selected from: wood, metal, plastic, and mixtures thereof.
58. The composition of any one of the preceding claims, wherein the composition is formulated to be applied to at least a portion of a surface of an article selected from: a table, a door, a door handle, or a mixture thereof.
59. The composition of any one of the preceding claims, wherein the composition is formulated to be applied to at least a portion of a surface of an article as a liquid composition, solid composition or gaseous composition.
60. The composition of claim 59, wherein the liquid composition, solid composition or gaseous composition, is formulated to dry in less than about: 5, 10, 15, 20, 25, or 30 minutes.
61. The composition of any one of the preceding claims, wherein the composition is formulated for an in vivo application.
62. The composition of any one of the preceding claims, wherein the composition is formulated for an in vivo application for a medical device, optionally selected from a catheter or an implant.
63. A coating or film comprising the composition of any one of the preceding claims.
64. A method of controlling, preventing and/or reducing the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof, the method comprising applying the composition of any one of claims 1 to 62, to at least a portion of a surface of an article.
65. Use of a composition of any one of claims 1 to 62, to control, prevent and/or reduce the concentration of at least one pathogen selected from: bacteria, fungi, mould, mildew, algae, viruses, and mixtures thereof.
66. Use of a composition of any one of claims 1 to 62 in the formation of an antipathogenic composition, film or coating.
67. Use of a composition of any one of claims 1 to 62, as an antifouling composition, film or coating.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2021904263 | 2021-12-24 | ||
AU2021904263A AU2021904263A0 (en) | 2021-12-24 | Coating Compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023115158A1 true WO2023115158A1 (en) | 2023-06-29 |
Family
ID=86900822
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2022/051584 WO2023115158A1 (en) | 2021-12-24 | 2022-12-23 | Coating compositions |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023115158A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106084305A (en) * | 2016-06-03 | 2016-11-09 | 苏州福德龙水产养殖有限公司 | A kind of preservative film containing nano material and preparation method thereof |
CN108708217A (en) * | 2018-04-28 | 2018-10-26 | 句容市茂源织造厂 | A kind of preparation method of antibacterial paste compound and its application in fruit packaging cardboard |
CN113278364A (en) * | 2021-05-26 | 2021-08-20 | 中山市富日印刷材料有限公司 | Environment-friendly post-processing paste and preparation method thereof |
-
2022
- 2022-12-23 WO PCT/AU2022/051584 patent/WO2023115158A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106084305A (en) * | 2016-06-03 | 2016-11-09 | 苏州福德龙水产养殖有限公司 | A kind of preservative film containing nano material and preparation method thereof |
CN108708217A (en) * | 2018-04-28 | 2018-10-26 | 句容市茂源织造厂 | A kind of preparation method of antibacterial paste compound and its application in fruit packaging cardboard |
CN113278364A (en) * | 2021-05-26 | 2021-08-20 | 中山市富日印刷材料有限公司 | Environment-friendly post-processing paste and preparation method thereof |
Non-Patent Citations (5)
Title |
---|
ANAND M., SATHYAPRIYA P., MARUTHUPANDY M., HAMEEDHA BEEVI A.: "Synthesis of chitosan nanoparticles by TPP and their potential mosquito larvicidal application", FRONTIERS IN LABORATORY MEDICINE, vol. 2, no. 2, 1 June 2018 (2018-06-01), pages 72 - 78, XP093077318, ISSN: 2542-3649, DOI: 10.1016/j.flm.2018.07.003 * |
BEGUM TOFA; FOLLETT PETER A.; MAHMUD JUMANA; MOSKOVCHENKO LANA; SALMIERI STEPHANE; ALLAHDAD ZAHRA; LACROIX MONIQUE: "Silver nanoparticles-essential oils combined treatments to enhance the antibacterial and antifungal properties against foodborne pathogens and spoilage microorganisms", MICROBIAL PATHOGENESIS, vol. 164, 21 January 2022 (2022-01-21), US , pages 1 - 9, XP086988873, ISSN: 0882-4010, DOI: 10.1016/j.micpath.2022.105411 * |
HASSAN YASSER A., KHEDR AMGAD I.M., ALKABLI J., ELSHAARAWY REDA F.M., NASR ALI M.: "Co-delivery of imidazolium Zn(II)salen and Origanum Syriacum essential oil by shrimp chitosan nanoparticles for antimicrobial applications", CARBOHYDRATE POLYMERS, vol. 260, 15 May 2021 (2021-05-15), GB , pages 1 - 14, XP093077311, ISSN: 0144-8617, DOI: 10.1016/j.carbpol.2021.117834 * |
SHANKAR SHIV, KHODAEI DIAKO, LACROIX MONIQUE: "Effect of chitosan/essential oils/silver nanoparticles composite films packaging and gamma irradiation on shelf life of strawberries", FOOD HYDROCOLLOIDS, vol. 117, 1 August 2021 (2021-08-01), NL , pages 1 - 12, XP093077315, ISSN: 0268-005X, DOI: 10.1016/j.foodhyd.2021.106750 * |
SHEHABELDINE AMR M.; HASHEM AMR H.; WASSEL AHMED R.; HASANIN MOHAMED: "Antimicrobial and Antiviral Activities of Durable Cotton Fabrics Treated with Nanocomposite Based on Zinc Oxide Nanoparticles, Acyclovir, Nanochitosan, and Clove Oil", APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, vol. 194, no. 2, 20 September 2021 (2021-09-20), New York , pages 783 - 800, XP037686108, ISSN: 0273-2289, DOI: 10.1007/s12010-021-03649-y * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mitra et al. | Antimicrobial copper-based materials and coatings: potential multifaceted biomedical applications | |
Page et al. | Antimicrobial surfaces and their potential in reducing the role of the inanimate environment in the incidence of hospital-acquired infections | |
Azevedo et al. | Polyethyleneimine and polyethyleneimine-based nanoparticles: novel bacterial and yeast biofilm inhibitors | |
Dunlop et al. | Inactivation of clinically relevant pathogens by photocatalytic coatings | |
Neethirajan et al. | Medical biofilms—nanotechnology approaches | |
He et al. | UV-assisted deposition of antibacterial Ag–tannic acid nanocomposite coating | |
Rtimi et al. | Quasi-instantaneous bacterial inactivation on Cu–ag nanoparticulate 3D catheters in the dark and under light: mechanism and dynamics | |
Sheridan et al. | Biomaterials: Antimicrobial surfaces in biomedical engineering and healthcare | |
JP2009506055A (en) | Bactericides using quaternary ammonium polymers and copolymers | |
Luo et al. | Antimicrobial activity and biocompatibility of polyurethane—iodine complexes | |
KR102455759B1 (en) | Antimicrobial Fabric Assembly | |
Mitra et al. | Transparent copper-based antibacterial coatings with enhanced efficacy against pseudomonas aeruginosa | |
Mitra et al. | Scalable aqueous-based process for coating polymer and metal substrates with stable quaternized chitosan antibacterial coatings | |
Weber et al. | Continuous room decontamination technologies | |
Sawada et al. | Self‐cleaning effects of acrylic resin containing fluoridated apatite‐coated titanium dioxide | |
Valiei et al. | Anodized aluminum with nanoholes impregnated with quaternary ammonium compounds can kill pathogenic bacteria within seconds of contact | |
Narayanan et al. | Inactivation of Acinetobacter baumannii biofilms on polystyrene, stainless steel, and urinary catheters by octenidine dihydrochloride | |
Hwang et al. | White light-activated antimicrobial paint using crystal violet | |
Hornschuh et al. | In vitro evaluation of contact-active antibacterial efficacy of Ti-Al-V alloys coated with the antimicrobial agent PHMB | |
André et al. | Evaluation of three different decontamination techniques on biofilm formation, and on physical and chemical properties of resin composites | |
Wasa et al. | Antimicrobial and biofilm-disrupting nanostructured TiO2 coating demonstrating photoactivity and dark activity | |
Ghosh et al. | Permanent, antimicrobial coating to rapidly kill and prevent transmission of bacteria, fungi, influenza, and SARS-CoV-2 | |
Wang et al. | Redox active Zn@ MOFs as spontaneous reactive oxygen species releasing antimicrobials | |
WO2023115158A1 (en) | Coating compositions | |
AU2022417292A1 (en) | Coating compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22908920 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022417292 Country of ref document: AU |